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ABSTRACT 
Background: Multiple sclerosis (MS) is a common neuroinflammatory and -degenerative 
disease. Magnetic Resonance Imaging (MRI) facilitates the diagnosis of MS, providing 
means to initiate early treatment and improving the long-term outcome. MRI can unveil MS 
in a pre-/subclinical phase as incidental findings in persons without typical MS symptoms, a 
condition called Radiologically Isolated Syndrome (RIS). New MRI techniques like synthetic 
MRI and phase-sensitive inversion recovery (PSIR) can further improve the visualization of 
MS pathology. Gadolinium-based contrast agents (GBCAs) are used in MS to evaluate 
disease activity but lead to retention of small amounts of gadolinium in the brain. These new 
developments highlight the need to constantly evaluate current and new MRI methods in an 
evidence-based manner to make informed decisions on how to optimize MS diagnostics. 
Study I investigated the incidence of RIS from a population-based perspective, in a Swedish 
region with high MS-incidence. All 2272 brain MRI scans performed in the county during 
one year were assessed by a senior radiologist and neuroradiologist for RIS. Only two cases 
of RIS was found, constituting merely 0.8 cases per 100,000 person-years, which is low 
compared to the MS-incidence in Sweden of 10.2 cases per 100,000 person-years. 
Study II compared the ability of conventional and synthetic PSIR to detect leukocortical 
lesions in 21 MS patients and studied the clinical relevance of the findings. The study showed 
that conventional and synthetic PSIR have comparable sensitivity for leukocortical MS 
lesions with excellent inter-rater agreement. Furthermore, the detected leukocortical lesion 
volumes were associated with lower cognitive scores, highlighting the clinical relevance. 
Study III retrospectively investigated gadolinium retention with conventional T1-weighted 
brain MRI. The dentate nucleus and globus pallidus were assessed in an 18-year follow-up 
study of 23 patients and 23 cross-sectional controls. Possible associations with cognitive 
deficits were also explored. The study showed that a higher number of GBCA administrations 
was associated with higher T1-signal intensity index in both the dentate nucleus and globus 
pallidus. After correcting for several factors related to MS disease severity, an association 
remained between higher signal intensity and lower verbal fluency performance. 
Study IV used simultaneous T1- and T2-relaxometry (synthetic MRI) to quantitatively assess 
the relationship between GBCA administrations and MRI relaxation rates (R1 and R2) in a 
prospective cohort of 85 MS patients along with 21 healthy controls without GBCA exposure. 
A higher number of administrations of linear, but not macrocyclic, GBCAs was associated 
with a dose-dependent increase in R1 and R2 in the studied structures (dentate nucleus, 
globus pallidus, caudate nucleus and thalamus). Furthermore, higher relaxation rates were 
associated with lower cognitive performance, but not increased physical disability or fatigue. 
Conclusions: RIS is a relatively rare phenomenon in a region with high MS-incidence. The 
RIS-incidence may, however, increase with improved MRI technologies and availability. 
Synthetic MRI provides PSIR that allows detection of leukocortical lesions with a similar 
sensitivity to conventional PSIR, without additional scan time. Linear GBCAs are associated 
with brain gadolinium retention that causes both T1 and T2 effects on MRI. These MRI signal 
changes are associated with lower cognitive performance, but that does not necessarily imply 
causality since the correlations may be confounded by MS pathology. 
SAMMANFATTNING 
Bakgrund: Multipel skleros (MS) är en vanlig neuroinflammatorisk och -degenerativ 
sjukdom. Undersökning med magnetkamera (MR) underlättar diagnostisering av MS, vilket 
bidrar till att tidig behandling kan sättas in och därmed förbättra den långsiktiga prognosen 
för MS-patienter. MR av hjärnan kan upptäcka MS i en pre-/subklinisk fas som bifynd 
hos personer utan typiska MS-symtom - ett tillstånd som kallas radiologiskt isolerat 
syndrom (RIS). Nya MR-tekniker som syntetisk MR och ”phase-sensitive inversion 
recovery” (PSIR) kan ytterligare förbättra visualiseringen av MS-plack. 
Gadoliniumbaserade MR-kontrastmedel används för att utvärdera sjukdomsaktivitet vid 
MS, men leder också till ansamling i hjärnan av små mängder gadolinium, som är en 
tungmetall. Befintliga och nya MR-teknikers för- och nackdelar behöver kontinuerligt och 
systematiskt utvärderas för att optimera MS-diagnostiken på ett evidensbaserat vis. 
Studie I, som utfördes i Västmanland, undersökte förekomsten av RIS ur ett 
befolkningsbaserat perspektiv. Alla 2272 MR-undersökningar av hjärnan som utfördes i länet 
under ett år bedömdes avseende kriterier för RIS av en senior radiolog, neuroradiolog och 
neurolog. Endast två fall av RIS hittades, vilket utgör 0,8 fall per 100 000 personår, vilket är 
lågt jämfört med MS-incidensen i Sverige, som är 10,2 fall per 100 000 personår. 
Studie II jämförde de två MR-sekvenserna konventionell och syntetiskt PSIR avseende deras 
förmåga att detektera MS-plack, som engagerar både vitsubstans och hjärnbarken, samt den 
kliniska relevansen av dessa fynd. Studien, som inkluderade 21 MS-patienter, visade att 
konventionell och syntetisk PSIR har jämförbar känslighet för dessa MS-plack med utmärkt 
överensstämmelse mellan bedömarna. Vidare kopplas volymen av dessa MS-plack till lägre 
kognitiv förmåga, vilket poängterar den kliniska relevansen. 
Studie III undersökte möjlig ansamling av gadolinium i hjärnan med konventionell T1-viktad 
MR. Intensiteten i två hjärnstrukturer (nucleus dentatus och globus pallidus) bedömdes hos 
23 MS-patienter, som följts under 18 år, och 23 friska personer. Eventuella kopplingar till 
kognitiv nedsättning undersöktes också. Fler antal kontrastmedelsadministrationer var kopplat 
till högre T1-signalintensitetsindex i bägge de undersökta hjärnstrukturerna. Efter korrektion 
för flera MS-relaterade sjukdomsfaktorer kvarstod en statistisk koppling mellan högre 
signalintensitet och lägre verbal ordflödesförmåga. 
Studie IV använde samtidig T1- och T2-relaxometri (syntetisk MR) för att kvantitativt 
bedöma förhållandet mellan gadoliniumbaserade kontrastmedelsadministrationer och MR-
relaxationstider (R1 och R2) i en prospektiv tvärsnittsstudie av 85 MS-patienter tillsammans 
med 21 friska kontroller, som inte exponerats för MR-kontrastmedel. Ett högre antal 
administreringar av linjära, men inte makrocykliska, kontrastmedel kopplades till en 
dosberoende ökning av R1 och R2 i de studerade strukturerna (nucleus dentatus, globus 
pallidus, nucleus caudatus och thalamus). Vidare kopplades högre relaxationstider i några 
strukturer i sin tur till lägre kognitiv förmåga, men inte till ökad fysisk funktionsnedsättning 
eller utmattning. 
Slutsatser: RIS är ett relativt sällsynt fenomen i en region med hög MS-incidens. RIS-
incidensen kan emellertid komma att öka med förbättrad MR-teknik och tillgänglighet. 
Syntetisk MR skapar en syntetisk PSIR som möjliggör detektion av MS-plack som passerar 
gränsen mellan vitsubstans och hjärnbarken.  Syntetisk PSIR har liknande känslighet 
som konventionell PSIR, utan ytterligare undersökningstid i MR-kameran. Linjära 
MR-kontrastmedel är förknippade med gadoliniumretention i hjärnan som orsakar både T1- 
och T2-effekter på MR; Dessa MR-signalförändringar är statistiskt associerade med 
lägre kognitiv funktionsförmåga, men det betyder inte nödvändigtvis att det 
föreligger ett orsakssamband eftersom kopplingen delvis kan förklaras av MS-sjukdomen. 
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1 INTRODUCTION 
1.1 MULTIPLE SCLEROSIS 
1.1.1 Background and diagnosis 
Multiple sclerosis (MS) is a neuroinflammatory and neurodegenerative disease that causes 
permanent damage to the central nervous system (CNS). In Greek, sclerosis means hardening 
and MS therefore refers to the multiple sites in the brain and spinal cord with hardened scar 
tissue. The inflammatory and degenerative processes in MS lead to a loss of myelin, which 
acts as an insulator of axons. The demyelination causes a disruption of the transmission of 
action potentials and can lead to permanent axonal loss, which gives the clinical symptoms 
in MS patients.1 MS is a leading cause of neurological deficits in the young population in the 
Western world.1 In Sweden, the disease is most commonly diagnosed at the age of 30 years 
and MS occurs more than twice as often in women than in men. The Swedish MS prevalence 
is around 189 per 100,000 and the incidence 6.0 to 10.2 per 100,000 person-years, which are 
among the highest rates globally.2–4  
The basis for diagnosing MS currently relies on the McDonald criteria, which require 
evidence of lesions in two or more locations in the CNS - ‘dissemination in space’ (DIS), 
which occurred at two different occasions - ‘dissemination in time’ (DIT). Definitions of DIS 
and DIT have changed over the years. The MS diagnosis was until recently made on the basis 
of the McDonald criteria from 2010,5 which was a revision of the two earlier versions from 
2005 and 2001,6,7 in which magnetic resonance imaging (MRI) has taken an increasingly 
larger role with each new revision. From the 2010 revision of the McDonald criteria, the 
radiological evaluation made it possible to demonstrate both DIS and DIT with a single MRI 
scan if at least one detected lesion showed activity - i.e. enhancement with a gadolinium-
based contrast agent (GBCA), in combination with non-enhancing lesions. The diagnostic 
criteria for MS were, however, updated once again in 2017.8 A major revision from a 
radiological perspective is the inclusion of MS lesions affecting the cortex. Obtaining a 
reasonable in vivo detection rate of cortical MS pathology is, however, challenging since it 
requires 7 Tesla (T) MRI or dedicated sequences such as phase-sensitive inversion recovery 
(PSIR) or double inversion recovery (DIR).9,10 The previous 2010 McDonald classification 
of DIS and DIT, which have been used in the studies of this thesis, are compared to the 
updated 2017 version in Table 1. A large difference in the latest revision from a clinical 
perspective is that the presence of oligoclonal bands in the cerebrospinal fluid (CSF) in 
patients with only one clinical episode is enough to fulfill DIT and thereby the criteria for 
MS diagnosis if MRI can demonstrate DIS. Furthermore, Table 2 shows a comparison 
between three latest radiological DIS classifications from 2005, 2010 and the present 
classification from 2017,8,11,12 and Figure 1A illustrates an MS patient fulfilling all these 
classifications for DIS. It is, however, very important to note that the radiological 
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classification for DIS should not be applied blindly to all types of patients performing brain 
MRI scans.  
It is essential to exclude any differential diagnosis 
when assessing a patient with suspicion of MS, 
since other diseases can also lead to brain MRI 
findings that formally fulfill the radiological 
classification for DIS. The list of differential 
diagnoses of MS is extensive and an expert panel 
has tried to systematize the investigation. They 
came up with 79 clinical, laboratory and 
radiological “red flags” that are suggestive of an 
alternative diagnosis than MS and warrants further 
investigation.13 Some common differential 
diagnoses with white matter (WM) changes that 
can mimic MS on MRI are vascular diseases 
(Figure 1B), migraine or other neuroinflammatory 
diseases such as neuromyelitis optica. 
Figure 1A. A T2-weighted FLAIR image, 
from Karolinska University Hospital, of a 
25-year-old MS patient with 
periventricular (open arrow), juxtacortical 
(closed arrow) and infratentorial (double 
open arrows) WM anomalies typical for 
MS. 
Figure 1B. A T2-weighted FLAIR image, 
from Karolinska University Hospital, of a 
patient with periventricular and 
subcortical WM anomalies consistent with 
age-related vascular disease. 
3 
Table 1. Comparison of the 2010 and 2017 revisions of the McDonald criteria.5,8 
Clinical 
attacks 
2010 Lesions with 
objective clinical 
evidence 
2017 Lesions 
with objective 
clinical evidence 
2010 Additional criteria to make the 
diagnosis 
2017 Additional criteria to make the 
diagnosis 
≥ 2 ≥ 2 or 1 lesion(s) with 
reasonable historical 
evidence of a previous 
attack 
≥ 2 lesions None. Clinical evidence alone is enough and 
differential diagnosis should have been 
considered. 
None, although MRI is always 
recommended if available. 
≥ 2 1 lesion 1 lesion DIS; OR await further clinical attack 
implicating a different site in the CNS 
None if the clinical attack corresponding 
to a lesion is clear-cut. If it is not a clear-
cut DIT, it can also be fulfilled by an 
additional attack or another lesion on MRI 
1 ≥ 2 lesions ≥ 2 lesions DIT; OR await a second clinical attack DIT; OR await a second clinical attack OR 
presence of oligoclonal bands in CSF 
1 1 lesion 1 lesion DIS; OR await further clinical attack 
suggesting a different location in the CNS 
AND DIT; OR await a second clinical attack 
DIS; OR await further clinical attack 
suggesting a different location in the CNS 
AND DIT; OR await a second clinical attack 
OR presence of oligoclonal bands in CSF 
0 1 year of disease progression AND at least 2 
of: DIS in brain MRI according to Swanton 
classification; DIS in the spinal cord based 
on ≥ 2 T2 lesions or positive CSF 
DIS=Dissemination In Space; CNS=Central Nervous System; CSF=Cerebrospinal fluid; DIT=Dissemination In Time; 
MRI=Magnetic Resonance Imaging.  
Changes between the 2010 and 2017 revision in bold. 
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Table 2. Comparison of the three latest versions of the radiological DIS classification  
DIS McDonald 200511 DIS McDonald 201012 DIS McDonald 20178 
Lesions in at least 3 out of: 
• ≥3 periventricular 
• ≥1 juxtacortical 
• ≥1 infratentorial or spinal 
• ≥1 contrast-enhancing or 
≥ 9 lesions 
Lesions in at least 2 out of: 
• ≥1 periventricular 
• ≥1 juxtacortical 
• ≥1 infratentorial 
• ≥1 spinal cord 
Lesions in at least 2 out of: 
• ≥1 Periventricular 
• ≥1 Juxtacortical/cortical 
• ≥1 Infratentorial 
• ≥1 Spinal 
Sensitivity 60% 
Specificity 88% 
Sensitivity 72% 
Specificity 87% 
Sensitivity and specificity similar 
as DIS 201014,15 
DIS=Dissemination In Space 
 
The time from symptom onset to MS diagnosis has been decreasing over the last decades 
because of developments in the diagnostic criteria and improvements in diagnostic 
techniques and routines.16 Early treatment initiation has been shown to be of vital importance 
to improve long-term outcome.17 The goal of each revised version of the diagnostic criteria 
has been to establish an MS diagnosis early with high sensitivity and specificity to thereby 
allow treatment initiation as early as possible.8 The sensitivity and specificity for the 2017 
revised DIS classification is not yet fully investigated. However, initial investigations have 
shown that the new McDonald criteria (mostly due to positive CSF sample) enables earlier 
diagnosis of MS after a first clinical event,18 with higher sensitivity,14,15 but perhaps with 
somewhat reduced specificity – at least according to a recent study.19 
1.1.2 Physical and cognitive evaluation 
MS is clinically characterized by the attacks and/or progression of physical disability. The 
global motor disability in MS is most commonly measured by using the Expanded Disability 
Status Scale (EDSS).20 EDSS is an ordinal scale ranging from 0 to 10, where 0 represents 
normal neurological functioning without findings in the neurological examination, while a 
score of 10 means death due to MS. The scores represent neurological impairment and 
increasing disability with certain landmarks, e.g. at EDSS 6 assistance is required to walk 
and at EDSS 7 the patient uses a wheel-chair. Furthermore, a majority of the MS patients also 
report fatigue that negatively affect their health-related quality of life.21 Fatigue is often 
evaluated using the Fatigue Severity Scale, a self-reported questionnaire with a 7-point 
grading scale and 9 questions, which has been shown to have great reliability and 
consistency.21,22 
While the physical manifestations of the disease may be obvious, up to 70 % of MS patients 
also have cognitive deficiencies that may be less apparent.23 It has also been suggested that 
MS in some cases can present with predominantly cognitive dysfunction.24,25 The awareness 
of cognitive impairment in MS has increased over the years and there are different 
neuropsychological tests and test batteries that are used for detecting cognitive impairment 
in MS. These test batteries are designed to evaluate different domains that are affected by 
MS. The most common test battery for evaluating cognitive function in MS, the Brief 
Repeatable Battery, is a fairly comprehensive set of tests that includes assessments of 
memory, language, attention, information processing speed and visuospatial function.26,27 
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More recently, a test battery called Brief International Cognitive Assessment for MS was 
recommended as a standard for evaluating cognition in MS. One study concluded that this 
newer test battery is more suitable than the Brief Repeatable Battery to use in everyday 
practice and research, especially when resources and time are scarce.28 However, in clinical 
practice, it may sometimes only be feasible to perform one single test and in those instances 
Symbol Digit Modalities Test (SDMT) is recommended since it is relatively sensitive to 
cognitive impairment in MS and only takes 90 seconds to perform.29 As SDMT is commonly 
used in clinical follow-ups of MS patients in our hospital, it was natural to include this test 
as measurement of cognitive function. The tests that were used in this thesis were:  
• SDMT, reflecting the information processing speed. The test participant has to decipher 
symbols (representing the digits 0-9) and then decode a sequence of symbols into digits 
as fast as possible. SDMT reflects primarily frontoparietal functions and has been 
shown to have good repeatability.29,30 
• Verbal Fluency Test, examining the word generation capacity – i.e. the performance 
to generate as many words as possible beginning with specific letters (in our case F, A 
and S, although other letter combinations exist).31 Decline in verbal fluency 
performance has predominantly been related to damage in the left frontal lobe.32,33  
• Rey Auditory Verbal Learning Test (RAVLT), assessing verbal memory function by 
recalling 15 words in five repetitions and then at a sixth delayed recall after 30 min. 
The test has been related to function in primarily the medial temporal lobes and 
temporal poles as well as hippocampal volumes for the delayed recall.31,34  
• Rey-Osterrieth complex figure test – copy (ROCFT), assessing the visuospatial 
organization and visual memory capacity by presenting a geometrically complex figure 
that is then re-drawn by hand from memory.31 ROCFT performance has been related to 
right hemisphere and prefrontal lobe functions.35,36  
1.1.3 MS subtypes 
In 1996, the National MS Society in the United States presented a description of four MS 
subtypes: relapsing-remitting MS (RRMS), secondary progressive MS, primary progressive 
MS and progressive-relapsing.37 These MS subtypes became internationally acknowledged 
and have been used in research and clinics to categorize the clinical phenotype of MS. The 
term 'relapse' refers to a period of clinical worsening of symptoms brought on by intermittent 
episodes of inflammation in the CNS. The progressive degenerative aspect of MS is still 
under debate, whether it is a secondary effect of inflammation or a separate disease process. 
As further understanding was made regarding the underlying pathology as well as the clinical 
course of MS, a revision of the subtyping was made in 2014,38,39 and implemented in the 
2017 revision of the diagnostic McDonald criteria.8 However, radiologically isolated 
syndrome (RIS), that in many cases can be considered to be the earliest detectable form 
representative of MS pathology, was not included as a subtype of MS. In the revision, 
progressive-relapsing MS was removed as a subtype. 
The revision further proposed that the different forms of MS should be specified as either 
active or non-active, based on the presence of clinical relapses or MRI activity 
(new/enlarging or contrast-enhancing lesions). The description of patients with progressive 
MS (Primary or Secondary progressive MS) should also include if any “progression” is 
present, i.e. gradual worsening of clinical symptoms. The potential advantages and caveats 
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of the new MS classification remain to be further studied, but it can hopefully help clinicians 
to better individualize MS therapies and facilitate research. 
1.1.4 Radiologically isolated syndrome  
The availability and use of MRI have increased in all OECD countries over the last decades.40 
Concurrently, improved MRI techniques provide higher image quality, higher spatial 
resolution and/or shorter scanning time. The higher quality and use of MRI increase the 
diagnostic accuracy, but also increase the frequency of incidental MRI findings.41  
MRI scans may unveil incidental WM anomalies with MS-like appearance among persons 
without previous suspicion of MS. The diagnosis of RIS was introduced by Okuda and 
colleges the diagnostic RIS criteria were defined (Table 3).42 The most common clinical 
indication for the initial MRI imaging leading to RIS diagnosis is headache.41 This has 
highlighted MRI as a method to possibly detect MS disease activity before it presents with 
clinical symptoms. RIS is clinically important since one-third of these patients will develop 
clinical symptoms consistent with MS within 5 years.41,43 
Okuda’s RIS criteria from 2009 was used in Study I of this thesis, but to better stratify RIS 
cases that are more likely to be subclinical MS, the MRI in MS group (MAGNIMS) recently 
published new assessment guidelines including consensus recommendations regarding the 
management of RIS.44 Early treatment is very important in MS to limit the accumulated 
neurological damage.17 However, it is unclear how RIS, which apparently in some cases is a 
manifestation of MS pathology in a pre-/subclinical form, should be monitored and if any 
MS treatment should be given. The MAGNIMS group concluded that there is not yet enough 
evidence to motivate initiation of disease-modifying therapies (DMTs) for RIS. Studies have 
identified risk factors for conversion of RIS to MS, such as a presence of spinal or 
infratentorial lesions.43,45 Those persons should at least benefit from regular clinical and 
radiological follow-ups.44 All DMTs have side effects and risks, which may outweigh the 
beneficial effects of an early treatment regime in RIS that eventually do not convert to MS. 
Therefore a multicenter treatment trial, to better explore the benefits of a treatment approach 
for RIS, is ongoing.46 
 
Table 3. Okuda’s criteria for RIS that have been used in this thesis.  
 
Criterion Requirement 
 Incidental WM anomalies in the CNS meeting the following MRI criteria: 
 A1. Ovoid, well-circumscribed, and homogeneous foci with or without 
involvement of the corpus callosum  
A A2. T2 hyperintensities measuring >3mm and fulfilling Barkhof criteria.11  
(≥3 out of 4) for dissemination in space 
 A3. CNS WM anomalies not consistent with a vascular pattern 
B No historical accounts of remitting clinical symptoms consistent with 
neurologic dysfunction 
C The MRI anomalies do not account for clinically apparent impairments in 
social, occupational, or generalized areas of functioning  
D The MRI anomalies are not due to the direct physiologic effects of substances 
(recreational drug abuse, toxic exposure) or a medical condition 
E Exclusion of individuals with MRI phenotypes suggestive of leukoaraiosis or 
extensive WM pathology lacking involvement of the corpus callosum  
F The CNS MRI anomalies are not better accounted for by another disease process 
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1.1.5 RIS epidemiology 
There are only a few studies on the incidence of RIS.41 These previous studies have been 
hospital-based studies from Sweden (Huddinge) and Pakistan. Interestingly, the higher 
incidence region for MS (Sweden) had a low frequency of RIS-cases (0.05%),47 while the 
low-incidence region for MS (Pakistan) showed a higher RIS frequency (0.7%).48 One study 
in relatives to patients with MS showed that up to 3% fulfilled RIS criteria, based on the 2005 
DIS classification, and 10% based on the 2010 DIS classification.49 
1.1.6 MS therapy 
MRI findings play a central role in personalizing MS treatment by making it possible to 
evaluate treatment efficacy in individual patients. The basis of MS treatment is DMTs. Since 
the first approval for treating RRMS with interferon β in 1993, many different DMTs have 
been developed. The DMTs aim to modulate immune functions thereby reducing the 
inflammatory activity, which in clinical trials has been shown to reduce the annual relapse 
rate, the number of new T2-lesions and the number of contrast-enhancing lesions.50 There 
are several DMTs to choose from when individualizing the treatment in regards to each 
patient’s risks and disease severity. Interferon β (Avonex, Betaferon, Plegridy, Rebif) and 
glatiramer acetate (Copaxone), which are administered as subcutaneous injections, have 
previously been considered to be first-line treatment. More recently oral alternatives as first 
line drugs have been registered, e.g. teriflunomide (Aubagio) and dimethyl fumarate 
(Tecfidera).51  
 
If the patients respond poorly to the first-line treatment (by clinical and radiological 
assessments), or if a more aggressive disease course is expected, the treatment can be 
escalated/initiated with alternatives such as natalizumab (Tysabri) or fingolimod (Gilenya) 
or the newly registered kladribin (Mavenclad),52 which have higher expected efficacy but 
also more potential severe adverse events such as opportunistic infections. In Sweden off-
label use of rituximab (MabThera) has proven to be a highly effective treatment with a 
favorable risk-benefit ratio with large potential cost savings compared to DMTs with 
indications for MS.53 A similar newly registered alternative to rituximab is ocrelizumab 
(Ocrevus). Additionally, if the inflammatory activity is high or very high (frequent clinical 
attacks or many contrast-enhancing lesions on MRI) alternatives such as alemtuzumab 
(Lemtrada) or Autologous Hematopoietic Stem Cell Transplantation (AHSCT) may be 
considered.50,54 
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1.2 MAGNETIC RESONANCE IMAGING 
1.2.1 MRI usage 
The clinical availability and use of Magnetic Resonance Imaging (MRI) for clinical 
diagnostic purposes has more than doubled in the last two decades.40 It is becoming one of 
the most important paraclinical tools for diagnostic investigations. In contrast to X-ray based 
techniques, such as computer tomography (CT), and nuclear medicine investigations that 
uses radioactive isotopes, MRI does not generate any potentially harmful ionizing radiation. 
Furthermore, MRI produces images with a much higher soft tissue contrast that increases the 
detection and characterization of specific findings, which in turn improves the diagnostic 
accuracy.55 One of the diseases where MRI has taken a primary role in both the diagnostics 
and clinical follow-up routine is MS.8 
 
MRI is usually a safe diagnostic tool, but there are, however, some safety considerations: 
Ferromagnetic objects that come to close to the strong magnetic fields can become dangerous 
projectiles and medical devices or implants can dysfunction. Energy from radiofrequency 
waves can cause heating of tissue as well as external material that potentially can harm the 
patient. High noise during scanning requires hearing protection.56 
1.2.2 MRI physics 
In short, clinical MRI techniques utilize very strong magnetic fields (in clinical settings 
usually 1.5 or 3 T) in combination with radio waves from transmitter coils that interact, 
resonate, with the inherent physical properties of the proton nuclei (most prevalent in water 
molecules) in the tissues. This creates echoes of radio waves from the protons that are 
measured by receiver coils (a sort of antenna) and used to create images of the body. A more 
foundational explanation of MRI physics and image reconstruction is beyond the scope of 
this thesis, but is reviewed in many text books, or articles on the subject.57 
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1.3 MULTIPLE SCLEROSIS AND MRI 
1.3.1 Current MRI protocols for MS diagnostics in Sweden 
MRI applications, especially in MS, have had an increasing importance since the introduction 
of MRI images (such as illustrated in Figure 2)58 that clearly showed its superiority to 
Computer Tomography in detecting specific pathologies.  
 
To improve the MS diagnostics nationally and to standardize 
the use of MRI in MS investigation and follow-ups in 
Sweden, neurologists and neuroradiologists wrote a national 
consensus agreement 2016 of the use of MRI in MS. The 
document included recommendations on MRI protocols, 
indications and frequency of use, as well as recommended 
the use of GBCA.59 The currently recommended MRI 
protocols are illustrated in Figure 3. A revision of the 
national guidelines of MRI in 
MS is expected in 2019 will 
likely reduce the usage of 
GBCAs during routine MS 
follow-ups.  
 
 
Figure 3. Swedish national MRI protocols for investigation and follow-up of MS.59 
 
1.3.2 Conventional MRI sequences 
For standard assessment of the MS lesions on brain MRI, T1-weighted imaging (T1WI), T2-
weighted imaging (T2WI) and fluid attenuating inversion recovery (FLAIR) images are 
currently primarily used. If possible, 3D sequences should ideally be used to achieve higher 
spatial resolution to reduce partial volume effects and thereby improve the detection rate of 
small lesions.60 T1WI with administration of GBCA is used to assess whether an MS lesion 
is currently inflammatorily active, what is referred to as a contrast-enhancing lesion. In 
contrast-enhancing lesions, there is a bright T1WI signal within the lesion due to leakage of 
the GBCA across the blood-brain-barrier. Detection of contrast-enhancing lesions or 
new/enlarging MS lesions on follow-up MRI is considered “disease activity” and especially 
valuable information for the clinician when deciding on the choice of therapy.  
Figure 2. An 18-year old 
female MS patient from the 
first published brain MRI 
of MS. The arrows show 
multiple MS lesions.58 
 
MRI investigation 
1. 3D T1 (non-enhanced) 
2. SWI 
3. Gadolinum-contrast agent 
4. Axial T2 
5. 3D T2-FLAIR 
6. 3D T1 (post contrast) 
  
MRI follow-up 
1. Gadolinium-contrast agent 
2. Axial T2 
3. 3D T2-FLAIR 
4. 3D T1 (post contrast) 
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1.3.3 Detection of cortical lesions with MRI 
Histopathological studies of MS have shown widespread involvement not only of the WM 
but also the grey matter in MS.61,62 Almost all MS patients have some degree of MS 
pathology in the cortex, even in the early stages of the disease, which causes a decline in 
cognitive abilities.63 It is clinically valuable to include assessment of cortical lesions, as they 
are a predictor of cognitive impairment and would increase diagnostic accuracy if included 
in the radiological readings.64,65  
 
The grey matter MS pathology is, however, hard to detect in vivo since the myelin content in 
the cortex is lower than in the WM, which reduces the contrast between demyelinated lesions 
and surrounding brain parenchyma.64 Figure 4 illustrates one common classification for 
different types of cortical lesions,62 of which leukocortical lesions (LCL, Type I) are the most 
easily detectible on MRI.66,67  
 
The detection of subpial lesions (type III) are especially difficult due to partial volume effects 
between the cortex and CSF.68 The inclusion of cortical lesions in the 2017 McDonald criteria 
therefore poses opportunities in improving MS diagnostics but also challenges since 
conventional MRI sequences have limited sensitivity to  
lesions in the cortex. Newer MRI sequences like DIR and PSIR can detect 1.5-5 times more 
cortical lesions than conventional sequences.69,70 It has been suggested to add PSIR or DIR 
into clinical MRI protocols, if such sequences are available.71 There are, however, technical 
limitations with these techniques (e.g. low signal-to-noise ratio, flow artifacts, non-
uniformity of the magnetic field in the cortex) and the inter-rater agreement for cortical 
lesions remains moderate.71 Therefore, the cortical lesion criterion for DIS was integrated 
with the more conventional juxtacortical lesions in the 2017 McDonald criteria.8,60 Figure 5A 
shows how an intracortical lesion can be more or less easy to detect on different MRI 
sequences and Figure 5B shows a leukocortical lesion visualized with DIR. Another way to 
improve the detection of cortical lesions is to increase the MRI field strength. T2* imaging 
at 7 T MRI has recently been shown (with histopathological verification) to more than double 
the detection rate of cortical lesions compared to a 3 T scanner, and can also detect diffuse 
cortical MS pathology beyond focal lesions.72,73  
Figure 4. Classification of cortical lesions according to Bø L et al.62: 
Type I: Leukocortical 
Type II: Intracortical 
Type III: Subpial lesion 
Type IV: The whole cortex 
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1.3.4 Synthetic MRI 
Synthetic MRI is an MRI technique that is 
able to quantify absolute MRI parameters 
(R1, R2, proton density with correction for 
field inhomogeneities), which can then be 
used to synthesize MRI weighted images with different virtual echo, repetition and inversion 
times.74,75 This turbo-spin-echo saturation-recovery sequence uses four acquisitions with 
alternating slice acquisition order, which effectively results in four different saturation 
delays; This, in combination with two echo times, results in 16 different images for each 
voxel that is used for the fitting of the T1- and T2-relaxation curves. Synthetic MRI can 
thereby provide images with multiple weighted images, such as T1WI, T2WI, T1- and T2-
weighted FLAIR as well as DIR and PSIR from a single acquisition. The technique is 
currently, however, based on a 2D acquisition with a need for gaps between slices to avoid 
interactions between slices. This being said, the quantitative aspect of the technique makes it 
possible to accurately compare the MRI measurements longitudinally and between patients.75 
Figure 5B exemplifies the detection of a cortical lesion with conventional and synthetic MRI. 
Figure 5A. A cortical MS lesion in a 42-year-old male with RRMS and 15-year disease 
duration illustrated with the following MRI sequences: MPRAGE (A), PSIR (B), Synthetic 
MRI PSIR (C) and Synthetic MRI DIR (D). The MRI scan was performed at Karolinska 
University Hospital in Huddinge 
 
Figure 5B. DIR sequence 
illustrating a leukocortical lesion 
(extending from the white matter 
into the cortex) in a 45-year-old 
woman with 3 years’ disease 
duration of RRMS. 
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1.3.5 Detection of central venules with MRI 
Since early histopathological descriptions of MS, it has been known that MS lesions occur 
around small venous vessels, called a central venule.76 T2*-weighted (as illustrated in Figure 
6)77 or susceptibility weighted imaging (SWI) have been shown to be able to detect these 
central veins in vivo. It has therefore been 
suggested that adding the detection of central 
veins into the MS diagnostic procedure would 
improve the radiological specificity for suspected 
MS cases, and may add prognostic information.78 
Studies have shown that both 3 and 7 T MRI can 
visualize central veins in many MS lesions.79 In 
a study comparing the two field strengths, 7 T 
was able to demonstrate around twice as many 
lesions with central veins compared to 3 T. The 
authors concluded that 7 T in this way is helpful 
to discriminate between microangiopathic and 
MS WM lesions.80 Apart from the potential to be 
useful in the radiological evaluation of MS, T2*-
weighted sequences are also sensitive to blood 
residuals and can therefore be helpful when 
excluding differential diagnoses, during 
investigation of patients with suspected MS.77  
 
 
 
 
1.4 MRI CONTRAST AGENTS 
1.4.1 MRI contrast agents 
The development of MRI contrast agents was initially motivated by how iodine-based 
contrast agents had showed added value for Computed Tomography for certain clinical 
applications, such as differentiating tumors and peritumoral edema.81,82 The subsequent 
development of contrast agents also for MRI has since been shown to have many diagnostic 
advantages to improve image quality and give additional information on functional tissue 
characterization.83 Contrast-enhanced MRI has been shown to be especially important to 
detect focal lesions, such as tumors, abscesses and metastasis; characterize lesions (e.g. 
benign vs. malignant tumors); give functional information and for use in MR angiography.84 
MRI contrast agents can have paramagnetic or superparamagnetic properties. Typically, 
specific metal ions are used in the contrast agents, which affect the T1- and T2-relaxation in 
the adjacent tissue. This strengthens the image contrast between the voxels containing the 
contrast agent and surrounding tissue with no or lower concentration of the contrast agent. 
The absolute majority of contrast agents are paramagnetic, which mainly shorten the T1-, but 
to some degree also shorten the T2-relaxation. The paramagnetic metal used in contemporary 
clinical settings is gadolinium in different types of GBCAs.85 There are also other examples 
of MRI contrast agents that have been used clinically. Manganese is such a paramagnetic 
metal with similar relaxation properties as gadolinium but it is currently not available in any 
Figure 6. A T2*-weighted image 
showing a central vein in a subcortical 
MS-lesion.77 
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commercial products.85 Contrast agents containing iron ions are instead superparamagnetic, 
which affects mainly the T2 relaxation, leading to signal loss on T2-weighted images. Iron-
containing agents are presently not commercially available either.85 
1.4.2 Gadolinium-based contrast agents  
Gadolinium is a metal belonging to the lanthanides. GBCAs are used for a wide spectrum of 
indications to improve diagnostics. During the early years of GBCAs, it was considered safe 
in all patients,86 but after safety concerns regarding nephrogenic systemic fibrosis (NSF), see 
1.4.3, it was considered safe only in patients with normal renal function.87 Possible short-
term reactions include allergic reactions (e.g. hives, sneezing, anaphylactoid reactions), 
physiologic reactions (such as nausea) or complaints related to the injection site (pain or 
coolness). The total amount of short-term adverse events has been reported to be < 2.4%, 
although serious short-term adverse events are as uncommon as 0.01-0.03%, with no 
statistically significant difference in the risk between the different GBCAs88 Most types of 
GBCAs are excreted through renal filtration and have a half-life of around 60-90 minutes, 
but a few GBCAs have partial excretion through the liver. Table 4 lists the characteristics of 
the GBCAs that have been commercially available as well as the types that recently were 
withdrawn from the market in Europe.89  
 
Unchelated gadolinium (Gd3+) is a toxic substance that may cause liver necrosis, 
hematological effects, splenic degeneration and blockage of calcium channels.85,90 Gd3+ is 
therefore chelated when used in GBCAs to prevent toxic effects. The chelate binds to the 
gadolinium and stabilizes it.85 The chemical stability varies depending on the chelate. Those 
with lower stability have a higher degree of in vivo dissociation of Gd3+, which is insoluble 
in its free form or soluble when bound to peptides, proteins or other macromolecules. 
Dissociation of Gd3+ in vivo almost immediately leads to binding to other molecules, such as 
citrate and phosphate.91 The different GBCAs are categorized into linear (open-chain chelates 
with lower stability) and macrocyclic types (with higher stability).92 They can further be 
categorized by their ionic potentials or how strong their relaxation capabilities are. It has been 
shown in vitro that the non-ionic linear GBCAs are the least chemically stable and ionic 
macrocyclic GBCAs have the highest stability.93 A visualization of the molecular structures 
of the GBCAs studied in this thesis is presented in Figure 7. 
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Table 4. Characteristics of clinically used GBCAs.94 
 
Gadolinium 
Based Contrast 
Agents 
Product 
Name 
Chelate 
Class 
Ionicity Hepato-
biliary 
excretion 
EMA decision 
for market 
approvals 
Gadodiamide Omniscan Linear Non-
ionic 
No Suspend 
Gadoversetamide OptiMARK Linear Non-
ionic 
No Suspend 
Gadopentetate 
dimeglumine 
Magnevist Linear Ionic No Suspend 
(except for 
intra-articular 
administration) 
Gadobenate 
dimeglumine 
MultiHance Linear Ionic Yes,  
1-4% 
Restrict to liver 
scans 
Gadoxetate 
disodium 
Primovist, 
Eovist 
Linear Ionic Yes,  
42-51% 
Restrict to liver 
scans 
Gadofosveset 
trisodium 
Ablavar, 
Vasovist 
Linear Ionic Yes, 5% Already 
discontinued 
Gadoterate 
meglumine 
Dotarem, 
Magnescope 
Macrocyclic Ionic No Continued  
Gadobutrol Gadavist, 
Gadovist 
Macrocyclic Non-
ionic 
No Continued 
Gadoteridol ProHance Macrocyclic Non-
ionic 
No Continued 
EMA = European Medicines Agency.  
 
Figure 7. Examples of a few of the molecular structures of GBCAs from the different 
classes. 
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1.4.3 Nephrogenic systemic fibrosis 
Since its introduction 1987, over 450 million doses of GBCAs have been administered with 
relatively few safety concerns,88,95,96 except for some rare adverse events.97,98 However, in 
2006, an association was made between nephrogenic systemic fibrosis (NSF) and GBCA 
administrations.87 NSF is characterized by fibrosis of the skin and internal organs. Most cases 
of NSF have been observed with the linear non-ionic contrast agent gadodiamide 
(Omniscan), which is the least chemically stable GBCA.93 It is therefore believed that it is 
the dissociated form, Gd3+, which activates the immune response causing the excessive 
collagen production leading to NSF. The majority of NSF cases have been observed in 
patients with renal failure. Most of the GBCAs are excreted through renal filtration. Patients 
with impaired renal function therefore retain chelated Gd3+ in the body for a longer period of 
time. This increases the risk of Gd3+ to dissociate and thereby leads to higher parenchymal 
exposure.99 Since the discovery of NSF, patients with risk factors for renal dysfunction 
undergo an evaluation of their renal function prior to any MRI scan with GBCAs. This has 
led to a marked drop in the number of NSF cases.88 Furthermore, many hospitals have also 
been inclined to mainly use the chemically more stable macrocyclic GBCAs. 
1.4.4 Gadolinium retention 
It had already in the early 1990s been shown in rodent models (with normal renal function) 
that gadolinium can be retained in many body parts, such as the skin, bone and liver after 
administrations of GBCAs.100,101 It was later shown that the gadolinium retention in those 
tissues were up to 30 times greater with non-ionic linear GBCAs than macrocyclic GBCAs.102 
In 2014, Kanda and colleagues published results showing that the number of linear GBCA 
administrations was associated with increased T1-signal in the DN and GP in patients with 
normal renal function.103 In this pivotal study, a Signal Intensity Index (SII) was calculated 
to quantify the image brightness by dividing the measurement of the investigated brain 
structure with measurements of another reference region within the same image acquisition 
according to the following equation:  
 
 
 
This SII method made retrospective analyses of brain MRI scans possible, although with the 
assumption that retention of gadolinium would not be significant in the reference region. 
Numerous MRI studies with similar methodology have later shown that administrations of 
linear GBCAs are associated with higher T1-weighted SII also in other brain structures.104–
109 Furthermore, histopathological studies have since validated that the increased SII 
corresponds to gadolinium retention.106,107,110,111 A study using a quantitative approach (T1-
relaxometry) also corroborated these findings by showing that a higher number of linear 
GBCA administrations was associated with higher T1-relaxation rates in the DN.109 A similar 
relaxometry-based method did not show any association for the macrocyclic GBCA 
gadobutrol,112,113 although a third (more recent) study did show a higher T1-relaxation rate 
in the GP in the gadobutrol-group compared to controls.114 It is not fully established which 
forms of gadolinium (dissociated or bound in the original chelate) cause the higher T1 signal 
intensity in these brain regions. The fact that it accumulates in a higher degree for linear 
GBCAs suggests that it gets retained to a larger extent in a de-chelated form.91  
 
SII = 
Signal intensity measured JO region of interest (ROI)
Signal intensity measured in a reference region
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It is unclear if gadolinium retention in the brain causes any clinically important or even 
detectable deficits. Studies that investigate potential negative neurological or cognitive 
effects and symptoms of gadolinium retention are thus needed, especially for patient groups 
that are repeatedly exposed to GBCAs, such as MS patients. A large study from Ontario, 
Canada, of 99,739 patients who had received GBCAs for a non-neurological indication, did 
not show any significantly higher risk to develop Parkinson’s disease than among 146,818 
patients who had performed non-GBCA-enhanced MRI. However, the analysis had a 
limitation in that merely 2.4% of the patients receiving GBCA had gotten more than three 
GBCA administrations.100 Another recent study in MS patients did not show any association 
to worsening of EDSS scores.115 The studies in this thesis are among the first to scientifically 
try to investigate the relationship of GBCA administrations and cognitive impairment. 
Preliminary results from a study at the Mayo clinic did not show GBCA-exposure to be a 
significant risk factor for cognitive performance.116 
1.4.5 Gadolinium-based contrast agents in MS 
GBCA-enhancing lesions provides temporal information of the MS disease activity, as 
contrast-enhancing lesions have most likely arisen within a few weeks before the MRI 
scan.117 It may also increase the sensitivity to detect new MS lesions during follow-up 
scans.118 It has been considered important to include GBCAs both in diagnostic investigations 
and follow-up MRI scans in order to have the best possible sensitivity to disease activity, 
which facilitates selection of appropriate DMTs and change of treatment regime when 
necessary. However, the increased efficacy of MS treatments has led to a lower frequency of 
contrast-enhancing lesions on follow-up MRI scans.119 As MS patients in the early disease 
stages are recommended to be followed-up with MRI at least every 6 months (first and second 
follow-up) and then every 12 months, it is important to moderate the use of GBCAs to avoid 
unnecessary exposure.59 When the disease treatment has stabilized (i.e. no detectable disease 
progression), follow-up scans without GBCAs should be considered.59 
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2 AIMS 
 
This thesis aimed to explore the clinical value of conventional and new MRI applications in 
MS and how they could be used to evaluate different features of MS in pre-/subclinical and 
more advanced disease stages respectively. The thesis further aimed to explore brain 
gadolinium retention in MS and its potential negative effects. The aims of the studies were: 
 
Study I 
To investigate the population-based incidence of RIS in an area with high prevalence of MS 
and how it was affected by different versions of the DIS classification. 
 
Study II 
To compare the ability to detect leukocortical lesions in MS between conventional and 
synthetic versions of PSIR and volumetrically investigate the associations with cognitive and 
physical dysfunction. 
 
Study III 
To investigate the longitudinal relationship of administrations of GBCAs with increased SII 
in the DN and GP, as well as the association of SII with neuropsychological performance in 
MS. 
 
Study IV 
To use MR-relaxometry to quantify the R1 and R2 values in different brain regions and 
explore their associations to exposure of linear and macrocyclic GBCA in MS. A secondary 
aim was to assess possible associations between relaxometry values and cognitive 
dysfunction. 
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3 MATERIAL AND METHODS 
3.1 ETHICAL CONSIDERATIONS 
All studies were approved by the Regional ethics review board in Stockholm. Registration 
numbers:  
- Study I: 2014/385-31/1  
- Study II: 2013/1635-31/2 
- Study III: 21/95, 04-906/4, 2012/858-31/2, 2016/1468-31  
- Study IV: 2013/1635-31/2, 2016/1468-31 
 
3.2 PATIENTS, PARTICIPANTS AND RADIOLOGICAL 
ASSESSMENT 
All radiological assessments and measurements in the studies were performed blinded to all 
MRI scanning details as well as all clinical and patient data.  
 
Study I. All performed brain MRI scans (in the year 2013) from the only two MRI centers 
in Västmanland County, were included in the study. In the first step, all MRI scans were 
anonymized and assessed by an experienced radiologist (Ayad Antwan). All MRI scans 
without any WM anomalies as well as patients with known MS were excluded. In a second 
step, a neuroradiologist (Juha Martola) evaluated the radiological parts of the RIS criteria 
(Okuda’s RIS criteria A and E, presented in more detail in Table 3). For comparison of the 
importance of different DIS classifications, both the 2005 and 2010 versions were evaluated. 
Written informed consent, was obtained to study patient history and neurological 
examinations in the patient charts, were retrieved from the patients that fulfilled the 
classification for DIS. Exclusions due to other likely causes for WM anomalies (Okuda’s RIS 
criteria B-D and F) were made in consensus between a radiology resident (Yngve Forslin) 
and a professor of neurology (Sten Fredrikson) with specialization in MS. 
 
Study II. In total, 21 MS patients were prospectively recruited from the Neurology 
Department at Karolinska University Hospital in Huddinge, to perform conventional and 
synthetic PSIR in addition to the normal follow-up protocol for MS. Patients with 
contraindications for MRI investigation, other neurological diseases or previous trauma to 
the head, were excluded. The demography of the patients is illustrated in Table 5. The 
conventional and synthetic PSIR images of the 21 MS patients were anonymized and 
randomly divided into two collections. Each collection contained images of only one set of 
either conventional or synthetic PSIR from all 21 patients. Two neuroradiologists (Farouk 
Hashim and Juha Martola) then individually assessed these collections separately during two 
rating sessions. The two neuroradiologists together then performed a third consensus 
assessment, which was considered “gold standard”. All assessments were performed with a 
delay of 12 weeks to avoid any bias caused by potential recollection from previous 
evaluations. 
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Study III. Over 18 years, 23 MS patients were prospectively followed-up with at least 3 MRI 
scans in 1996, 2004 and 2013. During the last follow-up in 2013, 23 age- and gender-matched 
healthy controls were also recruited for comparison. The patients had received different 
numbers of the linear GBCAs gadodiamide (Omniscan) and gadopentetate dimeglumine 
(Magnevist). Only 6 patients had received one administration of the macrocyclic agent 
gadoterate meglumine (Dotarem), as further detailed in Table 5. After anonymizing and 
randomizing the order of MRIs, a neuroradiologist (Farouk Hashim) performed manual 
measurements on the T1-weighted images using 2D regions of interest in the clinical Picture 
Archiving and Communication System (Sectra IDS7/dx, v. 15.1, Sectra Imaging IT Solutions 
AB, Linköping, Sweden). For anatomical guidance, and to avoid MS lesions, simultaneous 
assessment was performed of the corresponding T2-weighted images. To quantify the T1-
signal intensity, a SII was calculated with the middle cerebellar peduncle and thalamus as 
reference regions for the DN and GP respectively. 
 
Study IV. In the period from January to June 2015, 88 consecutive patients with MS who 
performed brain MRI at Karolinska University Hospital in Huddinge were recruited for 
additional imaging with Synthetic MRI. After exclusion of 3 patients due to imaging artifacts 
(1) and previous brain trauma (2), the study included 85 MS patients who had previously 
received GBCAs. Additionally, 21 healthy controls were included in the study. The patients 
were stratified into three groups based on the type of previously administered GBCAs with 
a macrocyclic group consisting of 15 patients who had only received the macrocyclic agent 
gadoterate meglumine (Dotarem) and a linear group of 11 patients who only had received the 
linear gadodiamide (Omniscan) and/or gadopentetate dimeglumine (Magnevist). The 
remaining 59 patients had received between 1-4 administrations of gadoterate meglumine 
(Dotarem) and 1-9 administration of gadodiamide and/or gadopentetate dimeglumine. This 
last group was therefore entitled the mixed group. The median times since the last GBCA 
administration was 7 months for the macrocyclic group, 52 months for the linear group and 
12 months for the mixed group. See Table 5 for more details. In all study participants, the 
longitudinal (R1) and transversal (R2) relaxation values from Synthetic MRI were extracted 
from manual segmentations, by a resident in radiology (Yngve Forslin), of the DN, GP, CN 
and thalamus. These deep grey-matter structures were chosen as they were easy to delineate 
and had been shown to be predilection sites of gadolinium retention.103–105,120,121 To assess 
the repeatability of the technique, scan-rescan acquisitions with repositioning of Synthetic 
MRI was performed in 14 MS patients and 17 healthy controls. 
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3.3 DEMOGRAPHY OF THE STUDIES 
3.3.1 Study I 
Västmanland County had a population of 259,000 inhabitants in the study year 2013.122 Since 
the healthcare in Sweden is divided into counties, the known population in combination with 
a complete coverage of all MRIs in the region made it possible to calculate a population-
based incidence of RIS. In total, 1,907 individuals (1,091 females, 816 males) in the ages 0-
91 years underwent a total of 2,272 brain MRI scans during 2013 (range 1-6 scans per 
individual) in Västmanland, Sweden. This equaled to 877 brain MRI scans per 100,000 
person-years. The mean age at the MRI scans was 47 years and Figure 8 illustrates age 
distribution in the study. 
 
 
Figure 8. The age distribution by gender of the participants in Study I. 
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Table 5. Demography of the study 
population in Study II, III and IV and 
available data on T1- and T2-related 
measurements and GBCA-exposure. 
Study II Study III Study IV 
 MS 
patients 
(N=21) 
Healthy 
controls 
(N=23) 
MS patients 
with GBCA-
administrations 
(N=23) 
Healthy 
Controls 
(N=21) 
Mixed MS 
group (N=59) 
Linear MS 
group 
(N=11) 
Macrocyclic 
MS group 
(N=15) 
Females/Males, N 14/7 18/5 18/5 11/10 18/41 8/3 11/4 
Age at the MRI scan, years 45 ± 12 56 ± 7 59 ± 6 36 ± 14 44 ± 10 51 ± 11 37 ± 14 
Disease duration, years 15 ± 10 - 19 ± 10 - 13 ± 8 20 ± 9 5 ± 6 
MS subtype, RR/SP/PP (for Study II at 
baseline in 1995-96) 
13/7/1 
- 
18/5/0 
(baseline) 
16/7/0 (2004) 
2/21/0 (2013) 
- 
39/17/3 5/6/0 14/1/0 
Disease modifying therapy, N (%) 14 (67%) - - - 44 (75%) 5 (46%) 13 (87%) 
Number of GBCA administrations, 
median (range) - 
0 2 (0-12) - 
ß ß ß 
Number of Dotarem administrations, 
median (interquartile range) - - See in text 3.2 
0 2 (2) 0 3 (1) 
Number of Magnevist and Omniscan 
administrations, median (interquartile 
range) 
- - 3 (4) 
0 4 (3) 3 (5) 0 
Number of months since last GBCA-
administration, median (range) - - - - 
13 (3-172) 52 (24–172) 7 (3-14) 
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Study II Study III Study IV 
SII (Study III) or R1 (Study IV), Dentate 
nucleus, mean (±Standard Deviation), 
middle cerebellar peduncle as reference 
(Study III) 
- 
1.01 ± 
0.03* 
1.03 ± 0.04* 1.23±0.05 1.29±0.05 1.28 ± 0.05 1.27 ± 0.04 
SII or R1, Globus Pallidus, thalamus as 
reference - 
1.10 ± 
0.04** 
1.07 ± 0.06** 1.24±0.06 1.29±0.06 1.31 ± 0.05 1.28 ± 0.05 
R1, Thalamus - - - 1.12±0.04 1.15 ± 0.05 1.14 ± 0.05 1.14 ± 0.04 
R1, Caudate Nucleus - - - 0.91±0.03 0.95 ± 0.04 0.96 ± 0.03 0.94 ± 0.02 
R2, Dentate Nucleus - - - 15.9±0.96 16.6 ± 1.21 16.7 ± 1.96 16.0 ± 1.45 
R2, Globus Pallidus - - - 19.6 ± 1.24 20.9 ± 1.47 20.5 ± 1.74 21.3 ± 2.78 
R2, Thalamus - - - 14.6 ± 0.47 14.6 ± 0.50 14.5 ± 0.54 14.4 ± 0.38 
R2, Caudate Nucleus - - - 13.9 ± 0.50 14.8 ± 0.83 14.4 ± 0.62 14.2 ± 0.76 
Expanded disability status scale, score, 
median (interquartile range), N 
2.0 (2.0) 
- 
4.0 (2.9) - 2.0 (2.0) 
N=54 
2.5 (4.0) 
N=11 
2.0 (1.25) 
N=13 
Single Digit Modality Test, z-scores, 
median (interquartile range), N 
-0.48
(1.46) - 
-1.03 (1.99) - -1.04 (1.42) 
N=36 
-0.19 (1.66)
N=5 
-1.30 (1.48)
N=12 
Verbal Fluency Test, z-scores, N -0.37
±1.37 - 
-0.66 ± 1.16 - -0.23 ± 1.14 
N=17 
0.09 ± 1.69 
N=4 
-1.20 ± 1.88
N=6 
Fatigue Severity Scale, mean score, N 4.53 ± 
1.79 - 
- - 4.26 ± 1.86 
N=14 
4.20 ± 2.12 
N=2 
4.33 ±1.21 
N=3 
Values reported as mean ± standard deviations, unless otherwise specified. Relaxation values in ms-1. RR=relapsing-remitting, SP=secondary 
progressive, PP=primary progressive. SII = Signal Intensity Index. SII-difference between controls and MS patients in Study III: unpaired t-test 
*P = 0.001, **P < 0.001.  
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3.4 CLINICAL EVALUATIONS 
In Study I, all patients fulfilling DIS classification were assessed retrospectively by assessing 
their clinical patient charts with regards to RIS exclusion criteria. Those who fulfilled the 
RIS criteria at their MRI scan 2013 had thereafter been followed-up clinically by a 
neurologist to investigate MS diagnosis, including thorough clinical history, neurological 
examination and CSF sampling. In Study II, III and IV, EDSS was used as a measurement of 
global motor dysfunction together with SDMT for information processing speed and a verbal 
fluency test. In Study III, the neuropsychological evaluations were performed at baseline, 
after 9 and 18 years and additionally included RAVLT (verbal learning with encoding and 
30 min delayed recall) and ROCFT (organization and visuospatial construction ability). In 
Study II and III the cognitive testing was performed in conjunction with the MRI scans, by 
the same experienced neuropsychologist (Åsa Bergendal), while in Study IV the cognitive 
scores were retrospectively collected from the clinical charts. In Study IV only scores within 
6 months prior or after the MRI scan were included. Based on the patients age and sex, the 
cognitive test scores were transformed into normalized to z-scores based on normative data 
in the literature. 
 
3.5 IMAGE ACQUISITION 
Study I. All three scanners that existed in Västmanland County were covered by the study: 
two 1.5 T MRI scanners (Siemens Avanto and Symphony; Siemens Healthcare, Erlangen, 
Germany) and one 3 T MRI scanner (Philips Ingenia; Philips Medical Systems, Best, The 
Netherlands). The MRI brain protocols were individualized and differed depending on the 
indication for the scan, but they all included at least T1WI and T2WI with a slice thickness 
of £5 mm. The majority of the MRI protocols also included a T2-weighted FLAIR sequence 
and 42% of the scans were performed with GBCA-administration. The protocols used for the 
following indications were the only that did not include T2-weighted FLAIR sequence: 
arterial angiography, control post-intracranial hemorrhage or after aneurysm coiling, 
meningioma follow-up, investigating vestibular schwannoma or tumors near the pons. The 
details of the standard brain MRI protocol that were most often used in each of the three MRI 
scanners are presented in Table 6. 
 
Table 6. A general overview of the standard brain MRI protocols used in the three different 
MRI scanners in Västmanland county. 
 
MRI scanner Philips Ingenia Siemens Symphony Siemens Avanto 
Field strength 3 T 1.5 T 1.5 T 
Standard brain 
MRI protocol 
Axial T1WI, sagittal 
T1WI, axial T2WI, 
coronal T2WI, axial 
FLAIR, axial DWI 
Axial T1WI, sagittal 
T1WI, axial T2WI, 
coronal T2WI, axial 
FLAIR, axial DWI 
Sagittal T1WI, axial 
T2WI, coronal 
FLAIR, axial SWI, 
axial DWI 
Slice thickness  £5 mm £5 mm £5 mm 
Number (and 
percentage) of 
scans 
with/without 
contrast media 
790 (35%)/924 (41%) 169 (7.4%)/389 
(17%) 
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Study II and IV. A Siemens Trio 3 T MRI scanner (Siemens Healthcare, Erlangen Germany) 
was used for all participants in both studies. In addition to the normal clinical MRI protocol 
for MS,59 Synthetic MRI sequence was added to the protocol. The longitudinal and 
transversal relaxation rates were automatically extracted by a least square fit model that was 
applied to the data in the SyMRI software (v.11.0 Beta for Mac, Synthetic MR, Linköping, 
Sweden). Image acquisition parameters for Study II and IV are detailed in Table 7. In Study 
II, a conventional PSIR sequence was also added to the protocol. The synthetic PSIR in 
Study II was extracted by using a reconstruction of the longitudinal magnitude data of the 
T1 inversion parameters in the quantitative MRI sequence. 
 
 
Table 7. Image acquisition parameters used in Study II and IV. 
 Study II Study IV Study II and IV 
Sequence type Synthetic 
PSIR 
Conventional 
PSIR 
Synthetic 
MRI 
MPRAGE FLAIR 
Acquisition type 2D axial 2D axial 2D axial 3D sagittal 3D 
sagittal 
Matrix size 256 x 204 256 x 204 256 x 204 256 x 256 256 x 256 
In-plane resolution, 
mm 
0.9 x 0.9 0.9 x 0.9 0.9 x 0.9 1.0 x 1.0 1.0 x 1.0 
Slices, N 34 34 30 176 160 
Slice thickness, mm 3.0 3.0 4.0 1.0 1.0 
Slice gap, mm 1.5 1.5 1.2 - - 
Flip angle, ° 120 120 120 9.0 120, T2-
variable 
Repetition time, ms 4820* 
[6000] 
6000 4260* 2300 6000 
Echo time, ms 22/100* 
[10] 
10 22/100* 2.98 388 
Inversion time(s), ms 150/580/ 
2000/4130* 
[500] 
500 150/580/ 
2000/4130* 
900 2100 
Acquisition time, min 7:47 3:32 6:50 5:15 7:02 
*Synthetic MRI acqusisition parameters. Virtual settings for synthetic PSIR in brackets. 
FLAIR=fluid-attenuated inversion recovery, MPRAGE=magnetization-prepared rapid 
acquisition gradient echo, PSIR=phase-sensitive inversion recovery.  
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Figure 9. A comparison between the respective T1WI, T2WI, T2-weighted FLAIR images, 
proton density-weighted images, and PSIR images from conventional (top row) and synthetic 
(bottom row) MRI. The images are from a 50-year old female MS patient who was included 
in Study II. 
 
Study III. Brain MRI scans were performed at baseline, after 9 years and 18 years. The 
majority of patients also had MRI scans with GBCA administrations between these 
examinations. A non-enhanced T1-weighted spin echo sequence was acquired at baseline and 
at the 18-year follow-up with 5 mm slice thickness. At up to four examinations over the last 
nine years (minimum at 9- and 18-year follow up) an MPRAGE sequence with 1x1x1.5 mm 
resolution was included in the MRI protocol. The MRI acquisition parameters are described 
in Table 8. 
 
Table 8. MRI scanners and sequence parameters in Study III. 
Time point  Baseline 9-year  
follow-up 
18-year  
follow-up 
MRI scanner GE Signa Siemens Vision Siemens Avanto 
Field strength, Tesla 
1.5 1.5 1.5 
Sequence type  
TSE MPRAGE TSE MPRAGE 
Field of view, mm 
250 240 220 260 
Acquisition matrix 
192x256 256x256 224x256 256x256 
Slice thickness, mm 
5 1.5 5 1.5 
Repetition time, ms 
640 1350 553 1910 
Echo time, ms 
13 7 9.1 3 
Inversion time, ms 
- 300 - 1100 
Flip angle, ° 
90 15 90 15 
Number of averages 
2 1 1 1 
TSE=Turbo Spin Echo, MPRAGE=magnetization-prepared rapid acquisition gradient echo 
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3.6 VOLUMETRICS 
WM segmentations in Study II, III and IV, WM lesions were segmented using Lesion 
Segmentation Toolbox v. 2.0.12 (Technische Universität München, Munich, Germany) for 
Statistical Parametric Mapping v. 12 (http://www.fil.ion.ucl.ac.uk/spm/software/spm12; 
University College London, London, UK) based on T2-weighted FLAIR images.123,124 The 
probability maps of the WM lesions were binarized using FMRIB Software Library v. 5.0.9 
(Oxford University, Oxford, United Kingdom),125 with a 0.1 binarization threshold and 
manually corrected using ITK-SNAP v. 3.4.0 (University of Pennsylvania, Philadelphia, 
USA).126 In Study II, the corrections were made first by a resident in radiology (Yngve 
Forslin) and finally reviewed by a neuroradiologist (Farouk Hashim). In Study III and IV, 
the corrections to the WM lesion masks were made by another resident in radiology (Tobias 
Granberg). 
 
LCL segmentations in Study II were performed manually and separately on both the 
conventional and synthetic PSIR images in ITK-SNAP by a neuroradiologist (Farouk 
Hashim) based on the consensus agreement.  
 
Brain parenchymal volume segmentations in Study III was retrieved with the longitudinal 
stream of Freesurfer v. 5.3.0 (Harvard University, Boston, USA)127 and normalized to the 
estimated total intracranial volume to obtain the Brain Parenchymal Fraction. 
 
Region of interest segmentations (the DN, GP, CN and thalamus) in Study IV were 
performed by a resident in radiology (Yngve Forslin) using ITK-SNAP on synthetic T1WI 
and T2WI, as illustrated in Figure 10. In order to reduce partial volume effects, the edges of 
the structures were avoided. By using FMRIB Software Library tools version 6.0 
(http://fsl.fmrib.ox.ac.uk/fsl),128 each structures’ relaxation values were retrieved from the 
Synthetic MRI R1- and R2-maps. 
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Figure 10. Segmentations from Study IV in an MS patient who have had received 6 previous 
linear GBCA-administrations. A and C are T1-weighted images that show hyperintensities 
in the DN and the segmentations of the GP, CN and thalamus. E and G illustrates the 
corresponding R1-images. B and D illustrates T2-weighted images and the segmentation of 
the DN. F and H represents the corresponding R2-images in. The color scale for the 
represent the relaxation values 0–2.5 s-1 for R1 and 0-20 s-1 for R2. (Segmentations are only 
shown on the side of the left brain hemisphere). 
   
  28 
3.7 STATISTICS 
 
Software and statistical significance level 
SPSS 22.0 was used in Study I and II and SPSS 24.0 was use in Study III and IV. The 
statistical significance level was pre-defined as a P<0.05. Following Benjamini and 
Hochbergs version for adjustment of the false discovery rate,129 this level equaled 0.030 in 
Study II, 0.029 in Study III and 0.023 in Study IV.  
 
Normality 
Shapiro-Wilks test was used to evaluate normal distribution. When applicable, normal 
distribution was achieved with logarithmic transformation.  
 
Group comparisons 
Unpaired t-test was used to compare SII in MS patients and healthy controls in Study III. For 
non-normal distributed data, Wilcoxon signed-rank test was used for group comparisons in 
Study II. In Study IV, one-way Analysis of variance (ANOVA) with Hochberg post-hoc test 
was used to compare the relaxation rates in the different subgroups and healthy controls.  
 
In Study III, the MS patients were divided into groups depending on the number of received 
GBCA-administrations (0, 1-4 and 5-12) to be used in the repeated measures ANOVA to 
explore longitudinal changes in the SII during the 18-year follow-up. 
In Study IV, repeatability was assessed by the mean delta of the relaxation times of the two 
scans. 
 
In Study II, the Intraclass correlation coefficient was used to assess inter-rater agreement. 
 
Regression analyses 
Multiple linear regression was used in Study II to explore associations between LCL 
(independent variable) and cognitive test scores (dependent variables). In Study III and IV, 
multiple regression analyses were similarly used to explore associations between the number 
of GBCA and SII and relaxation values, respectively. In Study III SII and in Study IV R1 
and R2 were respectively used as independent variables to assess associations with global 
motor function and neuropsychological test scores. 
In study IV - as the macrocyclic and linear group merely had 6 and 4 patients respectively 
who had performed verbal fluency test and 3 and 2 patients who had performed fatigue 
severity scale test, the regression analyses for relaxation rates, verbal fluency performance 
and fatigue were only made within the mixed subgroup. Regression analyses for the 
information processing speed scores were made for both the mixed (N=36) and macrocyclic 
group (N=12) and EDSS for all groups. 
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4 RESULTS 
4.1 STUDY I 
4.1.1 RIS incidence 
Out of the 1,907 patients, 1,297 had no WM changes and 121 were patients with known MS. 
As illustrated in Figure 11, 447 patients were excluded due to Okuda’s RIS criteria A and E, 
leaving 42 patients fulfilling the 2010 DIS classification. Out of these, only 20 patients also 
fulfilled the stricter 2005 DIS classification. The most common indication for MRI among 
the patients with DIS was headache. The clinical causes for exclusions due to comorbidities 
that can lead to WM anomalies, such as dementia and cardiovascular events, are detailed in 
Table 9. After exclusions, two patients were found to fulfill the concurrent criteria for RIS. 
They both fulfilled the 2005 and 2010 classification for DIS. This equaled to a cumulative 
incidence of 0.1% per year among all performed brain MRIs in the county. From a 
population-based standpoint the incidence was 0.8 cases per 100,000 citizens and year. 
During the screening process of the 2,272 MRI examinations, the findings from the clinical 
radiological readings were tabulated by a resident in radiology (Yngve Forslin) and is 
summarized in Table 10.  
 
Figure 11. Flow-chart of the screening process in Study 
 
  
All patients undergoing brain MRI 
2013 in Västmanland
(1907)
White matter anomalies
(489)
No white matter anomalies
 (1297)
Known MS 
(121)
Fulfilling Okuda A
- DIS Barkhof and Swanton (20)
- DIS Swanton only (22)
RIS (2)
Not fulfilling Okuda A (DIS) or E 
(447)
Exclusion according to
Okuda B-D and F criteria
- DIS-Barkhof and Swanton (18)
- DIS-Swanton only (22)
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Table 9. Clinical parts of the RIS criteria B-D and F, as described by Okuda and colleagues,3 
and reasons for exclusions (right column). 
RIS 
criteria 
Requirement Number of 
excluded 
patients 
Examples 
B No historical accounts of 
remitting clinical symptoms 
consistent with neurologic 
dysfunction 
13 Optical neuritis (4), dysesthesia 
(4), hemiparesis (3), walking 
difficulties and positive Babinski’s 
sign (1), Lhermitte’s sign (1) 
C The MRI anomalies do not 
account for clinically apparent 
impairments in social, 
occupational, or generalized 
areas of functioning  
3 Dementia (3) 
D The MRI anomalies are not 
due to the direct physiologic 
effects of substances 
(recreational drug abuse, toxic 
exposure) or a medical 
condition 
2 Long-term alcohol abuse (2) 
E Exclusion of individuals with 
MRI phenotypes suggestive of 
leukoaraiosis or extensive 
WM pathology lacking 
involvement of the corpus 
callosum  
*  
F The CNS MRI anomalies are 
not better accounted for by 
another disease process 
22 Stroke (5), myocardial infarction 
(4), malignant tumor with 
chemotherapy (4), diabetes 
mellitus type 2 with long-term 
complications and hypertension 
(3), transient ischemic attacks (3), 
aortic stenosis (2), carotid artery 
stenosis (1),  
* The radiological RIS criteria E and A3 (Table 3) were assessed at the same time. 
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  MRI findings  N* 
Normal findings  654 
Neurodegenerative disorders  
Degenerative or unspecific white matter changes  
Marked perivascular spaces  
Other degenerative findings 
718 
489 
50 
33 
Cerebrovascular disorders  
Infarctions  
Intracranial bleedings  
Arterial stenosis, dissections  
Aneurysms  
Venous thrombosis  
Vasculitis  
Progressive supranuclear palsy 
Wernicke-encephalopathy 
Other cerebrovascular disorders  
444 
257 
154 
13 
11 
4 
3 
2 
1 
2 
Intracranial neoplasms 
Meningiomas 
Gliomas  
Suspected neoplasm or neoplasm of unknown origin 
Metastasis  
Intracranial lipomas 
Lymphomas 
Schwannomas 
Other neoplasms 
247 
104 
59 
38 
30 
6 
4 
3 
3 
Neuroinflammatory disorders 
MS findings in known MS patients 
Other and suspected demyelinating disorders 
160 
121 
39 
Sinonasal disorder  
Sinusitis, mastoiditis, polyps 
Other ear/nose pathology 
158 
156 
2 
Intracranial cysts  
Arachnoid cysts  
Pineal body cysts  
Neuroglial cyst  
Fissure choroid cyst  
Colloid cyst  
Epi-/dermoid cyst  
Unspecified cysts  
94 
30 
28 
7 
7 
4 
3 
15 
Malformations  
Cavernous venous malformation  
Developmental venous anomaly  
Arnold-Chiari malformations  
Mega cisterna magna  
Agenesis of the corpus callosum  
Dandy-Walker malformations  
Other malformations  
84 
20 
20 
11 
7 
5 
2 
9 
Hydrocephalus 
Normal pressure hydrocephalus 
Secondary hydrocephalus  
50 
40 
10 
Infectious disorders 
Encephalitis 
Meningitis 
Other infectious disorders 
16 
5 
5 
6 
Table 10. An overview of the 
radiological findings in the 1907 
patients examined during the year 
2013 in Västmanland County, 
Sweden. 
 
 
*Each finding has only been 
counted once per patient, although 
different types of findings in the 
same patient have been counted 
separately. 
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4.1.2 The RIS patients 
Both RIS patients had 3 periventricular, 1 juxtacortical and more than 9 WM anomalies, thus 
fulfilling both the 2005 and 2010 classifications for RIS. The first person with RIS was a 
previously healthy 61-year-old female, who performed a brain MRI scan due to headache 
and unspecific vertigo. She had no contrast-enhancing lesions. CSF-analysis showed 
oligoclonal IgG-bands, but a normal IgG-index. No neurological symptoms or findings were 
presented at the clinical assessment and she had no recollection of any previous MS-
associated symptoms. The second patient with RIS was a 66-years-old female that had 
performed the MRI scan after two episodes of suspected epileptic seizures. The clinical 
investigation (including electroencephalogram) had normal findings and no diagnosis of 
epilepsy was made. CSF-analyses were negative. The neurological examination was normal 
and there was no history of prior neurological events. The persons with RIS did not fulfill the 
concurrent McDonald 2010 criteria for MS and did not receive any therapy. They were 
followed-up and after 1 year – still with no symptoms that indicated MS. Images of the RIS-
patients are illustrated in Figure 12. 
 
 
 
Figure 12. The first (A1-A3) and second (B1-B3) person who fulfilled the 
RIS criteria. Periventricular lesions are shown with open arrows, and 
juxtacortical lesions with closed arrows. 
 
   33 
4.2 STUDY II 
4.2.1 Radiological comparison of conventional and synthetic PSIR 
The Intraclass Correlation Coefficient showed an excellent agreement between the raters for 
the LCL assessment (conventional PSIR: 0.79, P<0.001; synthetic PSIR: 0.87, P<0.001). 
Similar agreements were shown between each rater and the consensus agreement ratings 
(conventional PSIR: 0.91 and 0.97; synthetic PSIR: 0.92 and 0.94, P<0.001 for each rater 
respectively). The number of detected LCL on the two MRI sequences did not differ 
significantly from each other (P=0.47 and P=0.08 for the raters respectively). Figure 13 
illustrates the relationship between the two raters’ individual and consensus ratings. 
Apparently, there seems to be a larger dispersion between the neuroradiologists’ ratings in 
patients with fewer lesions 
and less relative difference 
for patients with higher lesion 
counts. There was, however, a 
significant but relatively 
minor difference between one 
rater’s LCL count on 
conventional PSIR and the 
consensus rating (P=0.008). 
Wilcoxon Sign Rank test 
further showed no difference 
between the manual LCL 
volume segmentations 
between conventional and 
synthetic PSIR (P=0.17). The 
comparisons between the 
counts and volumes are 
shown in Table 11. Figure 14 
illustrates two LCL and how 
they were segmented on 
conventional and synthetic 
PSIR. 
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Figure 13. Illustration of the lesion volumes (red 
triangles) and the relation between each rater’s lesion 
counts (blue circles and green stars) on conventional 
and synthetic PSIR, as well as their relation to the 
consensus rating (purple squares and line). 
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Figure 14. Comparison 
of two leukocortical 
lesions and their 
segmentations on 
conventional (B and D) 
and synthetic PSIR (A 
and C).  
Table 11. Comparisons of the radiological assessments of leukocortical lesions on 
conventional and synthetic PSIR. 
Conventional 
PSIR 
Synthetic 
PSIR 
P-value
conventional 
vs. synthetic 
PSIR* 
Consensus 
rating 
P-value
conventional/synthetic 
PSIR vs. consensus 
rating* 
Leukocortical 
lesion count, 
Rater 1, N 
7±17 5±26 0.47 5±30 0.14/0.06 
Leukocortical 
lesion count, 
Rater 2, N 
7±34 7±29 0.08 5±30 0.008/0.96 
Leukocortical 
lesion 
volume, mL 
0.53±2.46 0.32±2.89 0.17 
The values are presented as median ± interquartile range. *P-value by Wilcoxon sign rank test. 
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4.2.2 Associations to cognitive and motor function 
Larger LCL volumes were significantly associated with lower information processing speed 
(SDMT scores) on both conventional (β=-0.62, P=0.003, adjusted R2=0.35) and synthetic 
PSIR (β=-0.55, P=0.010, adjusted R2=0.26). A similar association was found with lower 
verbal fluency performance and larger volumes of LCL on both conventional (β=-0.51, 
P=0.019, adjusted R2=0.22) and synthetic PSIR (β=-0.43, P=0.054, adjusted R2=0.14). When 
combining the volumes of LCL with WM lesions from conventional MRI sequences, the 
associations with information processing speed (β=-0.66, P=0.001, adjusted R2=0.41) and 
verbal fluency (β=-0.52, P=0.015, adjusted R2=0.24) were both positively affected. The 
corresponding associations for synthetic PSIR were similarly positively affected for both 
information processing speed (β=-0.58, P=0.005, adjusted R2=0.31) and verbal fluency (β=-
0.47, P=0.030, adjusted R2=0.18). When looking at LCL volumes and EDSS scores or fatigue 
severity scores, no significant associations were found for neither conventional (EDSS: 
β=0.45, P=0.18; fatigue: β=0.04, P=0.88) nor synthetic PSIR (EDSS: β=0.60, P=0.12; 
fatigue: β=-0.03, P=0.89). 
 
4.3 STUDY III 
4.3.1 Signal intensity index and GBCA-
administrations 
The DN (P<0.001), but not the GP (P=0.19), was 
found to have higher SII in MS patients than in 
healthy controls, as detailed in Table 5. When 
looking at the MS patients only, there was an 
association between higher number of linear 
GBCA-administrations and higher SII in the DN 
(β=0.45, P<0.001) and GP (β=0.58, P<0.001) 
when correcting for age, MRI scanner and the 
type of T1-weighted sequence. This association 
is illustrated in Figure 15. The association 
remained also after adding EDSS and disease 
duration as correction variables both for the DN 
(β=0.43 P<0.001) and GP (β=0.58, P<0.001). 
For the latter two time points, 3D imaging 
allowed volumetric tissue segmentations of the 
lesion volumes and atrophy (brain parenchymal 
fraction), which could then be added as 
additional correction factors in the regression 
analyses (to broaden the characterization of the 
severity MS disease burden). After doing so, the 
multiple regression still showed an association 
with higher SII in the DN and GP (β=0.39, 
P=0.007 and β=0.64, P<0.001, respectively). 
The mean change of SII, between the first and 
last MRI scan (spanning over 18 years), was 0.06 
(6.0%) in the DN and 0.07 (6.7%) in the GP. This equaled a change of 0.009 (~1%) per 
Figure 15. Higher number of GBCA-
administrations were associated with 
increased SII in DN and GP. 
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received GBCA-administration. The repeated measures ANOVA with pairwise comparisons 
showed that SII, in patients who had received 0 and 5-12 administrations of GBCA, were 
significantly different from each other (DN: 1.01±0.24 vs. 1.08±0.032, P<0.001 and GP: 
0.96±0.128 vs. 1.09±0.53, P=0.013). The comparison between the patients who had 0 and 1-
4 GBCA administrations showed a similar trend (DN P=0.049. GP P=0.064). An example of 
the change of signal intensity in one MS patient is illustrated in Figure 16. 
 
Figure 16. A female MS patient who at baseline (A & D) had received 0 GBCA, and then 
increasing amount of received GBCA (1 and 8 doses at B & E and C & F respectively). The 
SII increased gradually from 1.03 to 1.05 and 1.09 in the DN (A-C); and from 1.00 to 1.12 
and 1.16 in the GP (D-F). 
 
4.3.2 Associations to cognition 
There was an association between high SII and low verbal fluency performance in the GP 
(β=-0.45, P<0.001) and a trend in the DN (β=-0.25, P=0.03), which remained after correction 
for EDSS and disease duration both in the GP (β=-0.49, P<0.001) and the DN (β=-0.28, 
P=0.012). When looking at auditory verbal learning, a similar association was seen only in 
GP, although both before (β=-0.35, P=0.003) and after (β=-0.33, P=0.006) correction for 
EDSS and disease duration. A trend was seen for SDMT after correction for EDSS and 
disease duration (β=-0.24, P=0.043). No associations were found for ROCFT. At the later 
time points, brain parenchymal fraction and lesion volumes were available. When 
additionally adding those factors as correction variables, there was only one significant 
association remaining – between high SII in the DN and low verbal fluency performance  
(β=-0.40 P=0.013), and a trend in the GP (β=-0.36 P=0.034). 
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4.4 STUDY IV 
4.4.1 Repeatability 
The median scan-rescan difference in all regions was 2.0% with a range of 0.8-2.1% in the 
DN, CN and thalamus. As illustrated in Table 12, the GP showed a median change of 4.1% 
and 4.2% respectively for the R1- and R2-measurements.  
 
Table 12. The change for the R1 and R2 between first and second repeated MRI scan. 
The repeatability of the scans is reported as the median (interquartile range) % difference 
between the scans (the absolute difference between the scans divided by their mean). 
4.4.2 Group differences 
One-way ANOVA showed a significant difference of R1 and R2 in all brain regions between 
the groups, except R2-values in the thalamus. Hochberg post-hoc analysis showed that the 
overall differences consisted of significantly different values between the linear and mixed 
subgroup in comparison with the healthy controls. These results are detailed in Table 13. 
4.4.3 GBCA-administrations and R1- and R2-values 
Within both the linear and mixed group, there was an association between higher number of 
administered linear GBCA and higher R1 in the DN (linear: β=0.52, P=0.002; mixed: β=0.57, 
P<0.001), GP (linear: β=0.51, P=0.004; mixed: β=0.43, P<0.001), CN (linear: β=0.41, 
P=0.020; mixed: β=0.45, P<0.001) and thalamus (linear: β=0.23, P=0.21; mixed: β=0.39, 
P<0.001). After correcting for age, and for the macrocyclic group also the number of received 
macrocyclic GBCA, the associations remained significant for these two groups in the DN 
(linear: β=0.50, P=0.005; mixed: β=0.54, P<0.001), GP (linear: β=0.50, P=0.009; mixed: 
β=0.37, P<0.001); but only significant for the mixed group in the CN (linear: β= β=0.33, 
P=0.07; mixed: β=0.39, P=0.001) and thalamus (linear: β=0.24, P=0.22; mixed: β=0.41, 
P<0.001). 
 
There was only an association between higher number of linear GBCA and higher R2-values 
in the mixed group: in the DN (β=0.30, P=0.006), GP (β=0.43, P<0.001) and CN (β=0.50, 
P<0.001), but not thalamus (P=0.32). These associations remained after age and number for 
macrocyclic GBCA in the GP (β=0.42, P<0.001) and CN (β=0.36, P<0.001), but not the DN 
(P=0.14).  
 
For the macrocyclic group, there was unexpectedly an association with higher R2 in the CN 
(before: β=0.36, P=0.03 and after correction for age: β=0.40, P=0.006), but not in either of 
the subgroups in the other brain regions (P=0.08-0.82). 
 
The relationship between the number of administered GBCAs and relaxation values in the 
different subgroups are illustrated in Figure 17 and all the results from these regression 
analyses are also presented in detail in Table 14. 
 Dentate 
Nucleus 
Globus Pallidus Caudate 
Nucleus 
Thalamus 
DR1 % 2.0 (3) 4.1 (5) 2.1 (3) 1.9 (3) 
DR2 % 2.0 (4) 4.2 (6) 0.9 (2) 0.8 (1) 
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Table 13. Hochberg post-hoc group comparisons after one-way ANOVA. 
 
Results by Hochberg post hoc test performed after One-Way ANOVA. 
R1 and R2 are presented as the subgroup mean in s-1 ± the standard deviation. *=p<0.023 
 Dentate nucleus Globus pallidus Caudate nucleus Thalamus 
 R1 R2 R1 R2 R1 R2 R1 R2 
Linear 1.28 
±0.05 
16.74 
±1.96 
1.31 
±0.05 
20.52 
±1.74 
0.96 
±0.03 
14.44 
±0.62 
1.14 
±0.05 
14.45 
±0.54 
Mix 1.29 
±0.05 
16.59 
±1.21 
1.29 
±0.06 
20.89 
±1.47 
0.95 
±0.04 
14.75 
±0.83 
1.15 
±0.05 
14.64 
±0.50 
Macrocyclic 1.26 
±0.04 
15.87 
±1.14 
1.27 
±0.04 
20.50 
±1.101 
0.93 
±0.02 
14.18 
± 0.74 
1.15 
±0.03 
14.55 
±0.48 
Controls 1.23 
±0.05 
15.86 
±0.96 
1.24 
±0.06 
19.63 
±1.24 
0.91 
±0.03 
13.88 
± 0.50 
1.12 
±0.04 
14.64 
± 0.47 
 
Linear vs.  
Controls 
0.026 0.32 0.012* 0.52 0.006* 0.28 0.41 0.87 
Mix vs.  
Controls 
>0.001* 0.14 0.004* 0.004* <0.001* <0.001* 0.020* 1.0 
Macrocyclic 
vs.  
Controls 
0.13 1.0 0.55 0.41 0.69 0.82 0.25 1.0 
Linear vs.  
Mix 
0.99 0.99 0.89 0.97 1.0 0.79 1.0 0.82 
Linear vs.  
Macrocyclic 
0.98 0.44 0.42 1.0 0.27 0.95 1.0 1.0 
Mix vs.  
Macrocyclic 
0.64 0.32 0.77 0.93 0.18 0.07 1.0 0.99 
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Figure 17. The number of linear (A and C), but not macrocyclic (E), GBCA was associated 
with higher R1-values in the dentate nucleus, globus pallidus and caudate nucleus. The 
mixed group (D) also showed significant association with higher R1 for thalamus as well as 
R2 in the globus pallidus and caudate nucleus, the linear or macrocyclic group (B and F) 
did not show. The healthy controls (with GBCA administrations: N=0) are represented in 
each group in the scatter plot. 
Number of Linear GBCA-administrations
6 5 4 3 2 1 0
R1
1.40
1.30
1.20
1.10
1.00
.90
Linear subgroup
0
43210
R1
1.40
1.30
1.20
1.10
1.00
.90
Macrocyclic subgroup
0 1 65432
Number of Linear GBCA-administrations
1 086420
R1
1.40
1.30
1.20
1.10
1.00
.90
Linear subgroup
Number of linear GBCA-administrations
1 086420
R2
24.00
22.00
20.00
18.00
16.00
14.00
Linear subgroup
Number of Linear GBCA-administrations
1 086420
R1
1.40
1.30
1.20
1.10
1.00
.90
Mixed subgroup
Number of linear GBCA-administrations
1 086420
R2
24.00
22.00
20.00
18.00
16.00
14.00
Mixed subgroup
Number of Macrocyclic GBCA-administrations
1 086420
R1
1.40
1.30
1.20
1.10
1.00
.90
Macrocyclic subgroup
Number of macrocyclic GBCA-administrations
1 086420
R2
24.00
22.00
20.00
18.00
16.00
14.00
Macrocyclic subgroup
Dentate Nucleus
Globus Pallidus
Thalamus
Caudate Nucleus
A
C
B
D
E F
 40 
Table 14. Associations between number of linear or macrocyclic GBCA and relaxation rates 
Linear group Mixed group Macrocyclic group 
Uncorrected Corrected** Uncorrected Corrected*** Uncorrected Corrected** 
DN R1 0.52, P=0.002* 0.50, P=0.005* 
 
0.57, P<0.001* 
 
0.54, P<0.001* 0.23, P=0.19 0.24, P=0.16 
DN R2 0.14, P=0.45 
 
0.04, P=0.83 0.30, P=0.006* 
 
0.17, P=0.14 
 
0.04, P=0.82 0.07, P=0.64 
GP R1 0.51, P=0.004* 0.50, P=0.009* 
 
0.43, P<0.001* 
 
0.37, P=0.002* 0.16, P=0.36 0.17, P=0.33 
GP R2 0.28, P=0.14 
 
0.26, P=0.19 
 
0.43, P<0.001* 0.42, P<0.001* 0.29, P=0.10 0.29, P=0.10 
CN R1 0.41, P=0.020* 0.33, P=0.07 
 
0.45, P<0.001* 
 
0.39, P=0.001* 
 
0.24, P=0.16 0.27, P=0.11 
CN R2 0.21, P=0.25 
 
0.06, P=0.72 
 
0.50, P<0.001* 0.36, P<0.001* 
 
0.36, P=0.032 0.40, P=0.006* 
Thalamus R1 0.23, P=0.21 0.24, P=0.22 0.39, P<0.001* 
 
0.41, P<0.001* 
 
0.28, P=0.10 0.27, P=0.12 
Thalamus R2 -0.21, P=0.26
 
0.15, P=0.44 
 
0.11, P=0.32 
 
0.16, P=0.17 
 
0.10, P=0.59 0.08, P=0.65 
All association results are given as beta coefficients. The healthy controls (with N=0 GBCA administrations) are included in regression analyses for 
each group. 
*P<0.023. **Corrected for the age. ***Corrected for age and number of macrocyclic GBCA administrations.
CN = Caudate Nucleus, DN = Dentate Nucleus, GP = Globus Pallidus.
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4.4.4 Associations to cognition and global motor function 
In the mixed group, as detailed in Figure 18 and Table 15, but not the macrocyclic group, 
higher R1 and R2 in the CN and R1 in the thalamus remained significantly associated with 
lower verbal fluency performance after correction for disease duration and lesion volumes 
(CN: R1/R2: β=-0.63/-82, P=0.007/0.010; thalamus R1: β=-0.51; P=0.011).  
R1 in the DN and R1 and R2 in the thalamus were the only remaining significant associations 
to lower information processing scores (SDMT) after correction for disease duration and 
lesion volumes (DN: R2: β=-0.37; P=0.014; thalamus R1/R2: β= -0.39/-0.45, 
P=0.011/0.002). 
When similarly assessing associations with the Fatigue Severity Scale (P=0.09–0.96) in the 
mixed group and global motor function (EDSS) (P=0.12–0.99), no significant associations 
were found for any of the brain regions in any of the groups. 
Figure 18. Associations between R1 and neuropsychological tests in the mixed group. 
Higher R1-values in the thalamus were associated with lower information processing 
speed/symbol digit modalities test (SDMT) (A) and caudate nucleus and thalamus with 
lower verbal fluency performance (B) after correction for multiple sclerosis disease 
duration and lesion volumes. 
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Table 15. Associations between relaxation values (R1 and R2) and information processing 
speed (SDMT) and verbal fluency performance (F-A-S test) in DN, GP, CN and thalamus. 
 SDMT N=36 Verbal Fluency test N=17 
 Uncorrected Corrected** Uncorrected Corrected** 
DN R1 -0.34, P=0.04 -0.35, P=0.026 
 
-0.38, P=0.18 
 
-0.31, P=0.17 
 DN R2 -0.41, P=0.012* 
 
-0.37, P=0.014* 
 
-0.06, P=0.82 
 
-0.004, P=0.98 
 GP R1 -0.32, P=0.07 
 
-0.29, P=0.12 
 
-0.43, P=0.16 
 
-0.21, P=0.44 
 GP R2 -0.18, P=0.32 
 
-0.11, P=0.52 
 
-0.37, P=0.23 
 
-0.37, P=0.14 
 CN R1 -0.46, P=0.005* 
 
-0.33, P=0.04 
 
-0.63, P=0.009* 
 
-0.63, P=0.007* 
 CN R2 -0.39, P=0.018* 
 
-0.21, P=0.26 
 
-0.52, P=0.04 
 
-0.82, P=0.010* 
 Thalamus R1 -0.45, P=0.005* 
0.002* 
-0.39, P=0.011* 
 
-0.59, P=0.017* 
 
-0.51, P=0.011* 
 Thalamus R2 -0.42, P=0.011* 
 
-0.45, P=0.002* 
 
-0.44, P=0.09 
 
-0.35, P=0.08 
 The associations are displayed as coefficient beta with each p-value. *P<0.023. 
**Corrections were made for lesion volume and disease duration. CN=Caudate Nucleus, 
DN=Dentate Nucleus, GP=Globus Pallidus, SDMT=Symbol Digit Modalities Test. 
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5 DISCUSSION 
5.1 STUDY I 
We performed a population-based study in Västmanland County in Sweden and found that 
RIS is a rather unusual finding with an incidence rate of 0.8 cases per 100,000 person-years 
in a high-incidence country for MS. This equals to approximately 1 RIS case per 10 
diagnosed MS cases. Our study did not show any difference in incidence when applying the 
latest classification for DIS (2010 McDonald criteria) at the time of the study, in comparison 
with the older Barkhof classification for DIS (used in the 2005 McDonald criteria and 
Okuda’s RIS criteria). It is, however, hard to generalize the results from one Swedish county 
because of many possible confounding factors, such as regional differences in MRI practices, 
availability of MRI scanners and technical differences in MRI parameters and sequences, as 
well as population-related risk differences. It is important to stress that these incidence 
numbers are the incidence of the clinical entity RIS as an incidental finding among patients 
referred for an MRI scan without neurological symptoms, and not the prevalence of RIS in 
the general population that would fulfill RIS criteria if they would have performed a brain 
MRI scan. It is also important to keep in mind that the DIS classification for MS is validated 
for use in patients with suspected MS and for WM anomalies that are consistent with MS and 
should not be applied to other patient categories without a second thought. A review of 
diseases that may mimic MS have summarized that 7-58% of patients with other conditions 
such as migraine, CNS vasculitis and Sjögren’s syndrome fulfill the 2005 classification for 
DIS.77 The radiological MS or RIS criteria should therefore be used with discretion and with 
consideration of possible MS mimics. 
We know that at least some people with RIS go on to develop MS, about 33% in 5 years and 
50% in 10 years.41,43 It has been hard to differentiate those that will advance to MS and those 
that have other causes for the MRI findings with the concurrent RIS criteria. It is therefore 
challenging to know how to manage these patients clinically. The goal should be to give 
treatment as early as possible to those patients that have preclinical/subclinical MS, while not 
overtreating patients that will not convert to MS. The MAGNIMS group recommendations 
for RIS, however, states that there is currently lacking evidence to support treatment for RIS 
and that the recommendation instead is to actively monitor (clinically and radiologically) 
persons with RIS with a higher likelihood of having a subclinical form of MS.44 The relatively 
high age of the RIS patients in our study was surprising, since the highest incidence of MS 
occurs at the age of 30 years in Sweden.4 These results suggest that RIS could reflect a more 
benign MS entity that is not in the same need for prompt initiation of treatment. However, 
one of the patients in this study performed the MRI scan due to headache and additionally 
was found to have oligoclonal bands in the CSF. Moreover, there have been studies showing 
high prevalence of headaches in MS, especially in relation to the time of first neurological 
symptom.130,131 Although headache is an unspecific symptom, the result of this study 
supports the idea to at least perform a primary neurological investigation of RIS patients in 
order to make a more informed decision on whether to perform further clinical follow-ups 
The main limitation of the study is the relatively low sample size, as the number of detected 
RIS cases was few, which makes the estimation of the RIS incidence less robust. Another 
limitation was that many of the MRI protocols that were used for different indications for 
MRI did not correspond with an MS-dedicated protocol. This can most likely have reduced 
the sensitivity for especially smaller WM anomalies. This difference in MRI protocols did, 
however, represent the true variation present in the clinical praxis. 
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5.2 STUDY II 
Recently, synthetic MRI has proved to be a time-efficient alternative to conventional MRI 
since multiple weightings, including synthetic PSIR, can be obtained from a single 
acquisition.75 The main result of our prospective cohort study is that synthetic PSIR and 
conventional PSIR are comparable in their ability to detect leukocortical MS lesions. The 
study also showed that LCL volumes on both PSIR sequences were similarly associated with 
cognitive deficits, which indicate that using any of the PSIR sequences may add clinically 
valuable information. 
 
Previous studies have shown that imaging of cortical MS pathology can increase the 
diagnostic accuracy for MS and that it may give prognostic information in borderline 
cases.8,64,132 The recently updated diagnostic criteria for MS therefore included assessment 
of cortical lesions in the DIS classification (Table 2). The results in our study support this 
specific change to the DIS classification since detection of cortical pathology (that is 
associated with cognitive deficits), was possible even with a clinical 3 T MRI scanner. 
Imaging of cortical lesions have, however, been proven to be challenging, especially using 
MRI scanners with field strengths typically used in clinics, 1.5 or 3 T. A study validating the 
findings from a 3D DIR sequence with histopathology, showed a detection rate of 
intracortical lesions of merely 18%.133 It has been suggested that PSIR is better suited than 
DIR for the task of detecting cortical lesions.134 However, using a multi-modal approach with 
several different MRI sequences (as was used as a golden standard in Study II) was preferred 
by the raters of this study, especially as delineation of the WM-cortical boundary was 
facilitated. This suggested methodology with multiple sequences is also in line with some 
previously proposed approaches.9,69,135,136 The significant association between LCL volume 
and cognitive dysfunction in combination with the lack of significant association to physical 
disability or fatigue, implies that the LCLs are primarily related to cognitive deficits. 
 
There were some limitations of the study. The small sample size made it unsuitable to 
perform subgroup analyses among the different MS subtypes. Due to the in vivo character of 
the study, no histopathological validation was available. Availability of 7T would likely have 
improved the golden standard assessment but that is not yet available in the Stockholm 
region. To avoid artefacts due to inter-slice cross-talk, a slice gap of 0.5 (1.5 mm) had to be 
used, which emphasize the advantage to complement synthetic MRI with 3D-based MRI 
sequences, as used in the golden standard in this study. Recent developments also hold 
promise of a 3D-based synthetic MRI approach.137 
 
5.3 STUDY III AND IV 
Study III and IV both investigated associations between previously received GBCA 
administrations and relaxation rates in different brain structures. As a higher relaxation rate 
gives an increased signal intensity on conventional T1-weighted MRI sequences, Study III 
could semi-quantitatively estimate the effect on signal intensity by indexing the measurements 
with a region that supposedly had less gadolinium retained (i.e. SII). The study then utilized 
the longitudinal information from the 18-year follow-up of the patients to better confirm an 
existing association. Study IV instead used a quantitative MRI sequence to more directly 
estimate both the longitudinal (R1) and transversal (R2) relaxation rates, without the need to 
measure an adjacent reference structure that also may have some degree of gadolinium retained 
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and thereby a risk of confound the results. Study IV, however, did not have longitudinal data 
and had a purely cross-sectional design, which is less optimal, and therefore was compensated 
with a larger sample size. Study IV used the same MRI scanner with the same protocol in all 
patients, which was not possible with the longitudinal design of Study III, where both scanners 
and sequences had been upgraded in the hospital between the follow-up scans. Study IV also 
explored the repeatability of synthetic MRI within the same MRI scanner, which was shown to 
be robust for measurements in DN, CN and thalamus, but with larger variance in GP.  
 
That fact that exposure to linear GBCA leads to retained gadolinium in the body and brain has 
been confirmed in numerous other studies.96 Some of these studies indicate that the retained 
gadolinium from linear GBCAs are caused by dissociated gadolinium that binds to 
macromolecules in the brain, whereas macrocyclic GBCAs maintain their chelated form.108,138 
In line with the hypothesized pathological process (caused by dissociated Gd3+) leading to 
nephrogenic systemic fibrosis - it is hypothetically more likely that the unchelated form of 
retained gadolinium (primarily caused by linear types of GBCA) may cause more pathological 
effects than macrocyclic GBCAs.92 The results from Study IV is in line with previous studies, 
which show that the concentration of retained gadolinium from macrocyclic GBCAs is much 
less than for linear GBCAs and may therefore also be thought to be less harmful. There is, 
however, an uncertainty in this speculative statement as the potential toxic effect of retention 
by either one of the (linear and macrocyclic) GBCA types is not confirmed. The macrocyclic 
subgroup in Study IV was also relatively small (N=15) with few GBCA-administrations 
(median N=3), which may have been too few to demonstrate a possible association, although 
the even smaller linear group (N=11) did demonstrate an association in most brain regions. 
At the moment, the most interesting and important questions regarding gadolinium retention 
are of how and to what degree the retained gadolinium may affect physiological functions in 
the tissue (especially in the brain). In both Study III and IV we looked at associations between 
SII/relaxation rates and neuropsychological test performance and in Study IV also global motor 
function and fatigue. In Study III, only a significant association between higher SII in DN and 
lower verbal fluency performance remained after correction for MS-related biomarkers. In 
Study IV, instead similar associations with lower verbal fluency remained with higher R1 in 
thalamus and CN (as well as R2 in CN), but not for the DN or GP. Study IV, but not Study III, 
showed a significant association between higher R1 in thalamus and R2 in both DN and 
thalamus and lower information processing speed that remained after correction for lesion 
volumes and disease duration. The discrepancy between the results of Study III and IV rises 
wariness of a possible type 1 error. Furthermore, both Study III and IV were performed in MS 
patients that to some degree suffer from the effects of their lesion burden and brain atrophy, 
leading to cognitive deficits, out of which information processing speed performance is 
especially affected.23 Decline in verbal fluency performance is also confounded by MS disease, 
but may generally be less common in MS in comparison to information processing speed.139 
Study IV, however, showed that gadolinium retention seems to occur more or less in many 
parts of the brain that makes it more difficult to infer any relation to specific clinical deficit.  
In summary, the statistically significant results from Study III and IV do not determine a 
causational relationship, but instead should encourage future studies on the subject for better 
confirmation or rejection of the null hypothesis. No association was found between relaxation 
rates and global motor function or fatigue in Study IV, which implies that future studies instead 
should focus on exploring potential effects in the cognitive domain.  
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6 CONCLUSIONS 
Study I 
RIS is an uncommon entity in a region with high incidence of MS. The sparsity of RIS 
highlights the need for large-scale and multi-center collaborative efforts to better characterize 
the entity. There may however be regional differences in the RIS incidence, and it may also 
change over time as the availability and usage of MRI increases. Updating the Okuda RIS 
criteria to harmonize with the (at the time of the study) concurrent McDonald 2010 MS 
criteria in terms of radiological classifications for DIS did not change the RIS incidence in 
our study.  
 
Study II 
Synthetic MRI can produce synthetic PSIR images comparable to conventional PSIR in terms 
of the detection rate of leukocortical lesions. Since synthetic MRI can produce PSIR on top 
of other spin-echo-based weightings, without extra scan time, this could be of value in the 
assessments of MS patients even at conventional field strengths. Furthermore, the detected 
leukocortical lesion volumes were associated with lower verbal fluency test scores and slower 
information processing in MS, suggesting that adding the assessment of leukocortical lesions 
into the radiological investigation practice is clinically valuable. However, combining 
different sequences to improve the certainty of the detection of cortical lesions was preferred 
by the raters, so ideally synthetic or conventional PSIR can be added as a valuable part of the 
“puzzle” together with other 3D MRI sequences in such a multi-parametric approach when 
evaluating cortical MS pathology. 
 
Study III and IV 
Gadolinium retention from linear GBCAs has a long-lasting effect on the signal intensity in 
the DN and GP, as well as in the CN and thalamus. Synthetic MRI can be used with good 
repeatability to extract R1 and R2 relaxometry values without the need for a reference region 
and thereby quantitatively detect changes related to gadolinium retention. 
 
Shorter relaxation times were related to lower information processing speed and verbal 
fluency performance. However, conclusions regarding causality between gadolinium 
retention and possible cognitive effects can, however, not be made confidently as it may be 
impossible to fully correct for confounding factors, such as disease related cognitive deficits 
in MS. The results may, however, be used to inspire as well as power future studies that 
explore associations between GBCA-exposure and negative effects on cognition. 
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7 FUTURE ASPECTS 
Although RIS is not classified as MS, it is important that persons with RIS are followed-up 
in a structured fashion, similar to how persons with Clinically Isolated Syndrome are 
managed. They should primarily be evaluated clinically by an MS-specialized neurologist 
and preferably go through a lumbar puncture to assess the presence of oligoclonal bands in 
the CSF. While the presence of oligoclonal bands seem to have a predictive role for the risk 
of converting from RIS to MS, there are also other promising biofluid markers whose role 
still remains to be studied. For example, neurofilament in CSF and serum, which is a marker 
of axonal injury,140 is becoming more frequently used biomarker in clinical practice. Such 
laboratory tests and other biomarkers associated with neuroinflammatory diseases may be 
helpful in pointing out cases that have a subclinical form of MS.  
It should also be possible to improve the clinical evaluation to better point out RIS cases that 
have a high risk of being constituted by subclinical MS. A recent study showed that an 
engineered glove was able to discriminate RIS-patients to have subtle relative finger 
movement dysfunction.141 To use new methods to find subtle motor dysfunction or perhaps 
subclinical cognitive impairment that the patients themselves are not aware of, is an 
intriguing idea to use as aid in deciding which patients are of greatest need to be followed-
up prospectively or in some cases directly start therapy. Furthermore, unspecific symptoms 
(such as headache) that traditionally have been thought not to be associated to MS, can be of 
value to reassess in that regard – especially if the patients fulfill the RIS criteria.130 Due to 
the rareness of RIS, future epidemiological studies should include a larger study population, 
which preferably is achievable through multi-center collaborations. Future studies should 
preferably adapt to the MAGNIMS consensus recommendations for the diagnosis of RIS, to 
better align with the use of the latest version of DIS and DIT classifications specified in the 
2017 revision of MS diagnosis. These recommendations also aim to better differentiate the 
RIS cases that are at risk to have a subclinical form of MS and may be of help to decide how 
to clinically investigate and follow-up the patients. Improved utilization of imaging 
techniques of cortical pathology and volumetric measurement of brain volumes and MS-
lesions (and possibly also molecular and metabolic imaging by positron emission 
tomography)142 will most likely play a larger role in differentiating and stratifying the patients 
for different treatments. 
Quantitative MRI methods, such as Synthetic MRI that can synthesize several different image 
weightings from a single sequence, may be beneficial for the clinical diagnostics. Recently, 
a new MRI technology referred to as MR fingerprinting similarly provides the same type of 
output and post-processing capabilities, although with a completely different acquisition 
scheme.143 However, the role of synthetic MRI and MR fingerprinting for MS diagnostics 
has not yet been fully crystalized. Future studies should further explore the possible 
diagnostic and prognostic advantages of synthesized images and fast volumetrics generated 
by these new quantitative MRI techniques. Further validation of the multi-parametric output 
across field strengths and vendors are also needed.  
Future prospective studies aiming to investigate possible negative neurological effects of 
gadolinium retention should be performed in other patient groups than MS patients or patients 
with other neurological disease. The neurological pathologies are obvious confounders for 
both physical and cognitive deficits. Examples of more suitable cohorts are patients that 
undergo regular contrast-enhanced MRI as a surveillance for hereditary malignancies such 
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as breast cancer or pancreatic cancer.  These patients are usually otherwise healthy and could 
feasibly undergo a brain MRI scan including a quantitative sequence (such as synthetic MRI) 
in conjunction with their routine MRI. Ideally, these patients should also undergo 
neurological and cognitive tests prior to entering their MRI screening program and then be 
followed longitudinally both neurologically, neuropsychologically and with MRI. Further 
investigation regarding cognitive outcomes after multiple administrations of GBCAs are very 
important for future guidelines of the use of GBCA. 
The age with highest incidence of MS is around 30 years in Sweden,4 and the national MRI 
guidelines for MS in Sweden currently recommends that GBCAs should be given at each 
follow-up, which at the beginning of the therapy initiation is fairly frequently. It is therefore 
important to conduct studies that explore both the benefits and risks, so that a well-weighted 
decision can be made for the patients regarding the use of GBCAs. In clinical practice, we 
can see that the benefits of using contrast agents is reduced when the patients are getting 
closer to the secondary progressive phase,59 but the question is when and at what terms we 
should put the threshold to avoid the GBCAs for MRI follow-ups. Additionally, one study in 
RRMS patients showed that only 24% had enhancing lesions at follow-up, and that all of 
them also had either more or enlarged lesions in comparison with the previous MRI scan. 
The presence of lesion enhancement did therefore not have any significant effect on therapy 
choice.119 However, such a retrospective study may not be fully generalized to other MS 
subgroups, and the need of GBCA administrations at follow-up MRI scans may have high 
clinical value only early after the diagnosis and therapy initiation and in patients that have 
not yet stabilized in their disease activity. Furthermore, in a master thesis from last year 
(2018), in our research group at Karolinska Institutet,144 an unexpectedly low occurrence 
(5.9%) of GBCA enhancing MS-lesions were found during a period of three months on three 
MRI-scanners at Karolinska University Hospital in Huddinge. Larger studies are needed to 
confirm if these results reflect a general trend with lower frequency of GBCA enhancements 
in MRI-follow-ups of MS patients.  
It is also possible that our current risk-benefit analysis for the use of GBCAs is altered when 
new diagnostic techniques and tools are emerging that could replace the use of GBCAs. In a 
longitudinal pilot study, follow-up MRI scans of glioblastoma brain tumors with quantitative 
T1-relaxometry, investigators were able to determine a T1-relaxation cut-off value that could 
predict which areas would be contrast-enhancing with a sensitivity of 86% and specificity of 
80%.145 This and other similar techniques that are able to compensate for not using GBCAs 
are encouraging if it means that we might be able to not use GBCAs and still preserve similar 
diagnostic accuracy. 
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